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68Ga-PSMA PET/CT in staging and restaging of Prostate Cancer
Patients: comparative study with 18F-Choline PET/CT
W Langsteger1, A Rezaee1, W Loidl2, HS Geinitz3, F Fitz1, M Steinmair1,
G Broinger4, L Pallwien-Prettner5, M Beheshti1
1PET-CT Center Linz, Department of Nuclear Medicine & Endocrinology,
St Vincent’s Hospital, Linz, Austria; 2Prostate Cancer Center Linz,
Department of Urology, St Vincent’s Hospital, Linz, Austria; 3Department
of Radiation Oncology, St Vincent’s Hospital, Linz, Austria; 4Department
of Radiology, St Vincent’s Hospital, Linz, Austria
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Aim: 11C- and 18F-choline PET/CT have been established as a prom-
ising modality in the assessment of prostate cancer patients1. How-
ever, it suffers to detect small malignant lesions. 68Ga-PSMA (PSMA)
PET/CT showed promising in the detection of small lesions with a
high tumor to background contrast2.
This study was designed for comparison of detection rate between
PSMA and 18F-fluoromethylcholine (FCH) PET/CT scan in pre or post-
op prostate cancer patients.
Methods: In this prospective study 15 consecutive prostate cancer
patients (mean age 67.9, range 57–83) underwent both PSMA and
FCH PET/CT with a maximum interval of 4 weeks without any treat-
ment in between. The imaging modalities were performed in 9 pa-
tients (mean age: 70.3; range: 63–83) in pre- and 6 Patients (mean
age: 64.2; range: 57–71) in post-operative setting.
Prostate cancer patients with histopathologic verification or biochem-
ical recurrence were included in this study. Patients with systemic
therapy and known second cancer were excluded. Pathologic findings
in each imaging modalities have to be clarified histopathologically or
by conventional imaging modalities and/or clinical follow-up.
Results: Staging: The mean of PSA was 35.1 ng/ml (range: 3.44 -
81.17 ng/ml). Pathologically increased tracer uptake was detected on
both imaging modalities in the prostate gland in all patients [mean
size on PSMA PET/CT: 20 mm (range: 12–43); FCH PET/CT: 23.6 mm
(range: 12–34) & mean SUVmax on PSMA PET/CT: 16.2 (range: 6.1-
28.1); FCH PET/CT: 7.4 (range: 3.6-15.9)].
Overall, a total number of 15 and 14 positive lymph nodes were
detected on PSMA PET/CT and FCH PET/CT images, respectively.
Malignant lymph nodes showed significantly higher uptake on
PSMA- comparing FCH PET/CT [mean SUVmax on PSMA PET/CT: 12.8
(range: 2.8-34); FCH PET/CT: 6.6 (range: 2.3-11.9)]. However, there was
no appreciable difference in the tracer intensity of the detected bony
lesions in each modality.
Restaging: The mean of PSA was 2.3 ng/ml (range: 0.48 - 5.35).
Local recurrence with pathologically increased tracer uptake was
detected in one patient on both imaging modalities, However, it
shows markedly higher uptake on PSMA PET/CT (SUVmax: PSMA:
12.4; FCH: 4.9).
In addition, PSMA PET/CT was able to detect higher number of meta-
static lymph nodes compared with FCH PET/CT (14 vs. 10) with sig-
nificantly better tumor to background ratio (SUVmax 8.7 on PSMA vs
4.45 on FCH).© 2016 The Author(s). Open Access This article
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifOne false positive bone lesion was detected on PSMA PET/CT study.
Although the MRI was negative, follow-up imaging was planned
within 4–6 months. Also, two false positive bone lesions were de-
tected on FCH PET/CT images in bilateral femurs. Moreover, PSMA
PET/CT was false negative in one bony lesion detected by FCH
PET/CT.
Conclusion: PSMA PET/CT reveals a more promising role for staging
and re-staging of prostate cancer patients even with low PSA level.
Markedly higher tumor to background contrast is seen on PSMA PET/
CT which allows higher detection rate especially in the small lesions.
However, the value of this modality in the assessment of bone
metastases should be further evaluated in future studies.
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of parathyroid adenoma?
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Aim: In this prospective multicenter study we assessed the value of
18F-Choline (FCH) PET – CT comparing 99mTc-Sestamibi SPECT-CT in
the detection of parathyroid adenoma in patients with primary
hyperparathyroidism.
Methods: Both 99mTc-Sestamibi SPECT-CT and FCH PET – CT
were performed in 74 consecutive patients with biochemical evi-
dence of primary hyperparathyroidism. At least one abnormal
99mTc-Sestamibi and/or FCH focus corresponding to a parathy-
roid gland or ectopic parathyroid tissue was considered as posi-
tive finding. Surgical exploration and resection was performed in
34 patients with positive findings in at least one imaging modal-
ity. The results of imaging modalities were verified with histo-
pathologic findings as the standard of truth.
Results: In patients who underwent surgery, mean serum calcium
and parathormone (PTH) level was 2.76 ± 0.32 mmol/l and 176.93 ±
165.30 pg/ml, respectively. Intraoperative PTH monitoring showed a
significant drop in PTH level in all patients. In a patient-based analysis,is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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patients (33/34) while 99mTC-Sestamibi SPECT-CT was positive in 62 % of
patients (21/34). The mean serum calcium and PTH levels of patients with
negative imaging modalities were 2.41 ± 0.24 mmol/l and 104.87 ±
41.33 pg/ml, respectively. The size and weight of parathyroid adenomas
in patients with only FCH PET – CT positive imaging were 14.1 mm and
1.5 g, respectively. Both imaging modalities were negative in 8 patients
with evidence of primary hyperparathyroidism.
Conclusion: In this prospective multicenter study, FCH PET – CT
showed promising results - clearly superior to 99mTC-Sestamibi
SPECT-CT - in the localization of parathyroid adenoma in patients
with primary hyperparathyroidism.A3
[18F]Fluoro-DOPA-PET/CT in the primary diagnosis of medullary
thyroid carcinoma
A Bytyqi1, G Karanikas1, M Mayerhöfer2, O Koperek3, B Niederle4,
M Hartenbach1
1Medical University of Vienna, Division of Nuclear Medicine, Vienna,
Austria; 2Medical University of Vienna, Division of General and Pediatric
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Aim: Evaluation of [18F]Fluoro-DOPA-PET/CT in patients with primary
medullary thyroid carcinoma (MTC) prior to total thyroidectomy and
lymph node dissection.
Methods: 33 patients with elevated basal calcitonin levels and patho-
logical peak stimulated calcitonin were examined with [18F]Fluoro-
DOPA-PET/CT prior to surgery. The post-operative histological findings
served as standard of reference for tumor- and lymph node detection.
Post-operative basal und stimulated calcitonin levels as well as follow-up
calcitonin were documented and correlated with pre-surgical parameters
(DOPA-PET SUV, PET/CT staging, bas./stim. calcitonin) by means of ROC-
Analysis and contingency tables.
Results: In all patients, primary MTC was histologically verified post-
surgery. 29 out of 33 patients showed increased DOPA-Decarboxylase
activity in the primary tumor (Sens.: 88 %; mean SUVmax: 10,3). Un-
detected tumors were exclusively staged pT1a. Lymph node staging
showed a sens./spec./acc./ppv/npv of 65 %/100 %/79 %/100 %/65 %
(P < 0,001). Pre-surgical cN1b-status in [18F]Fluoro-DOPA-PET/CT was
predictive for postsurgical persistently elevated calcitonin levels (sens.
85 %, spec. 90 %, ppv 85 %; P < 0.001), as well as pre-surgical basal cal-
citonin levels with an AUC of 0.84 (P = 0.009). SUV-parameters did not
show any significance in that matter.
Conclusion: [18F]Fluoro-DOPA-PET/CT detected increased DOPA-
Decarboxylase activity in almost all primary MTCs, with the exception
of few pT1a-tumors. Evaluation of lymph node status is highly spe-
cific and has a high positive predictive value, whereas a cN1b-stage
as well as highly elevated basal calcitonin levels are predictive for
post-surgical tumor persistency.A4
Variations of clinical PET/MR operations: An international survey
on the clinical utilization of PET/MRI
T Beyer1, K Herrmann2,3, J Czernin3
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Aim: This survey aims at gathering information about PET/MR opera-
tions worldwide to determine the current clinical applications of PET/
MR imaging.
Methods: An internet-based survey of active PET/MR users was ran be-
tween 05/2015 and 08/2015 using surveymonkey. All 69 active PET/MR
sites were invited to partake in this survey. The survey was composed
of 37 questions related to (A) PET/MR center and installation, (B) varia-
tions in imaging protocols and (C) potential future applications.Results: Responses were collected from 38 (55 %) sites: North America
(24 %), Europe (59 %) and APAC (17 %) corresponding to the regional
installations worldwide. Sites have operated PET/MR for (27 ± 16)
months with 58 % sites having 2+ years experience.
Sites used PET/MR for indications in oncology (66 %), neurology
(18 %), other (10 %) and cardiology (6 %). The most frequent indica-
tions in oncology are brain, prostate, gastrointestinal and head/neck
cancer. Tracers used most frequently for neuro-PET/MRI are [18F]FDG,
[18F]FET and amyloid imaging compounds. Likewise most frequently
used travers in oncology are [18F]FDG, somatostatin receptor ligands
and choline analogues. [18F]FDG was also most frequently used for
other applications.
Users consider oncology with a focus on prostate and head/neck
cancer a key application of PET/MR, as well as and neurology/neuro-
degenerative imaging. Pediatric imaging was named by one site
only. Responses to upcoming key applications were mixed, thereby
representing essentially the same variety of indications that PET/MR
is used for today with the exception that many sites anticipate more
frequent use of PET/MR in cardiac patients, and in patients with can-
cers of soft tissues, prostate and gynecological cancers.
Conclusion: An international survey among early adopters of PET/MR
reveals a mix of clinical routine and research applications with a
focus on oncology and neurology. The future of PET/MRI is seen in
expanded oncology and cardiac applications whereby system cost
and the ability to fully integrate MR and PET information are consid-
ered key promotional factors.
A5
Standard Dixon-based attenuation correction in combined
PET/MRI: Reproducibility and the possibility of Lean body mass
estimation
I Rausch1, P Rust2, MD DiFranco1, M Lassen1, A Stadlbauer3,
ME Mayerhöfer3, M Hartenbach4, M Hacker4 and T Beyer1
1Center for Medical Physics and Biomedical Engineering, Medical
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Medicine, Department of Biomedical Imaging and Image-guided
Therapy, Medical University of Vienna, Vienna, Austria
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Aim: To assess the reproducibility of standard, Dixon-based attenu-
ation correction (MR-AC) in positron emission tomography/magnetic
resonance (PET/MR) imaging and to evaluate the possibility of deriv-
ing a patient-specific lean body mass (LBM) from these MR-AC data
for LBM based SUV quantification.
Methods: Ten subjects who underwent a body composition meas-
urement using air displacement plethysmography (ADP) where in-
cluded in this study. Subjects were positioned in a fully-integrated
PET/MR system and three consecutive multi-bed acquisitions of the
standard MR-AC image data were acquired. For each subject and
MR-AC map, the following compartmental volumes were calculated:
total-body (TB), soft tissue (ST), fat (F) and intermediate tissue (IT).
Intra-subject differences in TB and sub-compartmental volumes (ST,
F, L and IM) were assessed by means of coefficients of variation (CV)
for all MR-AC maps and excluding those with major artifacts.
ADP measurements were used to calculate a reference LBM
(LBM(ADP)). A second LBM estimate was derived from available MR-
AC data: LBM(MR-AC) = (V(ST)*ρ(ST) + V(IM)*ρ(IM)*0.5)/(V(ST)*ρ(ST) +
V(F)*ρ(F) + V(IM)*ρ(IM))*BW, where V is the respective tissue volume,
ρ is the tissue-dependent density and BW is the body weight. An
additional LBM estimate was obtained from a gender-specific for-
mula (LBM(Formula)). Pearson’s correlation was calculated for
LBM(ADP), LBM(MR-AC) and LBM(Formula). Further, linear regression
analysis was performed on LBM(MR-AC) and LBM(ADP).
Results: Mean CV of the TB volume for all 30 scans was (2.1 ± 1.9)%.
When excluding missing tissue artifacts, the CV was reduced to (0.3 ±
0.2)%. Mean CV for the sub-compartments before and after excluding
artifacts was ST: (0.9 ± 1.1)% and (0.7 ± 0.7)%, F: (2.9 ± 4.1)% and (1.3 ±
1.0)%, and IM: (3.6 ± 3.7)% and (1.3 ± 0.7)%, respectively.
EJNMMI Research 2016, Volume 6 Suppl 1 Page 3 of 18Correlation was highest for LBM(MR-AC) and LBM(ADP) (r = 0.99). Lin-
ear regression of data excluding artifacts resulted in a scaling factor
of 1.06 for LBM(MR-AC).
Conclusion: LBM estimation from DIXON MR-AC maps correlates well
with standard LBM and thus offers routine SUV(LBM)-based quantifi-
cation in PET/MR. However, MR-AC images must be controlled for
systematic artifacts, like missing tissue and tissue swaps, which limit
MR-AC reproducibility.
A6
High resolution digital FDG PET/MRI imaging for assessment of
ACL graft viability
K Binzel1, R Magnussen2, W Wei1, MU Knopp3, DC Flanigan2, C Kaeding2,
MV Knopp1
1Wright Center of Innovation in Biomedical Imaging, The Ohio State
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Aim: Injury to the anterior cruciate ligament (ACL) is common, par-
ticularly among young athletes. Reconstruction with a graft helps re-
store stability and function to the knee, as the graft heals through
the process of ligamentization1. Anatomic imaging alone cannot pro-
vide insight as to the progress of graft ligamentization, however.
Combined 18F-FDG PET/MR imaging on current systems has been
shown to be feasible for the evaluation of ACL graft viability following
reconstructive surgery. We evaluated the capabilities of high resolution
PET/MRI through combined use of a next generation digital photon
counting PET/CT and 3 T MRI in an on-going multi-modality imaging
study for the assessment of graft viability.
Methods: 10 patients had a standard of care MRI on a 3 T Ingenia
CX. Proton density and T1 weighted sequences were acquired on all
three planes, with a 3D high resolution image acquired on the sagit-
tal plane. Low-dose PET/CT acquisitions were performed on the Ver-
eos digital PET/CT (all Philips Healthcare). A foam mold of the MR
knee coil was used to match knee positioning between PET and MR
acquisitions. A single bed position centered on the knees was ac-
quired following a 111 MBq 18F-FDG injection. Listmode data were
reconstructed using a 144x144 matrix with 4 mm3 voxel volumes, a
288x288 matrix with 2 mm3 volumes, and a 576x576 matrix with
1 mm3 voxel volumes. Each reconstruction matrix size also used the
option of a Gaussian filter and point spread function correction. Pa-
tients were grouped according to time since surgery and SUVmax
was measured in the proximal, middle, and distal portions of the
graft, femoral and tibial tunnels, and the posterior cruciate ligament
(PCL), and quadriceps muscle for reference. Matched ROIs were
drawn in the contralateral healthy knee.
Results: In all cases, PET and MR images were readily co-registered
for quantitative evaluation. Excellent image quality was seen at all re-
construction matrix sizes, with the smaller voxel volumes improving
visual evaluation of the heterogeneity of uptake throughout the eval-
uated ACL grafts. As previously validated in phantom tests, the use
of smaller voxel volumes also improved quantification of graft meta-
bolic uptake. SUVs measured on 2 and 1 mm3 images were found to
be greater than those of default 4 mm3 images for regions of inter-
est in the graft and bone tunnels. SUVs in background regions were
less affected by the change in reconstruction matrix size. Addition of
the Gaussian filter and point spread function correction during re-
construction further improved visual and quantitative precision. As in
previous evaluation of ACL grafts by conventional PET, the trend was
seen whereby the metabolic activity in the graft and bone tunnels
decreased with longer recovery times since surgery.
Conclusion: PET/MRI imaging of the knee, particularly ACL grafts,
benefits from the improved signal to noise and capacity for higher
resolution reconstruction facilitated by use of PET digital photon
counting and digital MR coil systems. The primary advantage in
digital PET imaging of small structures is due to the improved quanti-
tative precision enabled by a reduction of partial volume effects.
Higher matrix PET reconstruction also enables better voxel-wise
registration to MRI. The improved accuracy of quantification withdigital PET will allow for more detailed analysis and correlation with
clinical evaluations of graft healing and rehabilitation planning fol-
lowing reconstructive surgery.
References
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Using pre-existing hematotoxicity as predictor for severe side
effects and number of treatment cycles of Xofigo therapy
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Aim: Hematopoetic toxicity is regarded a major problem of treat-
ment with Xofigo. In this study we analyzed whether pre-therapeutic
hematotoxicity (HT) influences the occurrence of side-effects.
Methods: In 54 patients with metastatic CRPC that underwent Xofigo
therapy data on hemoglobin-levels (Hb), number of platelets (Plts)
and leukocytes (Leuk) before, during and after therapy were col-
lected. Pre-therapeutic HT and adverse events (AE) were scored
(grade 0–4) according to the CTCAE recommendations. For further
analysis patients were categorized with regard to their initial HT
grade and correlated with development of severe HT (grade 3 or 4)
during therapy, and the number of Xofigo treatments.
Results: Among 54 patients 7 (13 %) demonstrated no pre-existing
HT (grade 0). These patients developed only mild HT (grade 1: 56 %;
grade 2: 22 %) and no severe HT. 37 patients (69 %) presented with
initial grade 1 HT. This group showed increasing HT in 48 % (grade 2:
35 %, grade 3: 11 %, grade 4: 3 %). Grade 2 initial HT occurred in 7
patients (13 %). Here HT grades showed a tendency to grade 3 (total
grade 3: 43 %, grade 2: 43 %) during therapy in all categories (Hb:
42.9 %; Plts: 42.9 %; Leuk: 28.6 %). Only one patient had an initial HT
grade 3, regarding his Hb values. This patient did not show a change
in HT level. Pre-existing HT correlated significantly with treatment-
induced HT (R = 0,47), with significantly different HT levels between
groups (P < 0,02) and significantly increased severe HT frequency (P <
0,005). Number of Xofigo treatment cycles was significantly different
between groups: group 0: 6; group 1: 5,5; group 2: 4,7; group 3: 4 (P <
0,05).
Conclusion: Higher grades of HT before Xofigo therapy were signifi-
cantly related to the development of severe HT during therapy,
mainly affecting hemoglobin values, thus leading to increasing num-
bers of premature termination of Xofigo treatment.
References
1. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treat-
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Aim: The development of our QDOSE software was inspired by the
need for a versatile, easy-to-use dosimetry software solution. Our ex-
perience in numerous clinical trials drove the design of QDOSE to in-
corporate all functionality within one stand-alone system. It has a
fully integrated workflow, validated methodology and advanced out-
put functionality.
Methods: QDOSE combines all dosimetry steps into a single soft-
ware. This includes loading of imaging data, 2D and 3D coregistration,
region and volume of interest (ROI / VOI) drawing and segmentation,
EJNMMI Research 2016, Volume 6 Suppl 1 Page 4 of 18curve fitting for time activity curves (TACs), calculation of cumulated
activities and dose calculation.
Dose calculation entails (1) export of residence times to the OLINDA/
EXM software [1], (2) spherical model dose calculation [2] imple-
mented as continuous interpolation model and (3) Voxel S dose calcu-
lation. It will also include MIRD / ICRP phantom-based safety dosimetry
calculation.
QDOSE incorporates all major workflows: (1) Planar Dosimetry featur-
ing quantitative methodology according to [3]; (2) Hybrid Dosimetry
using multiple time points of conjugate view imaging and one quan-
titative SPECT/CT imaging time point for improved quantification; (3)
3D Dosimetry using multiple time points of quantitative SPECT/CT or
PET/CT imaging; and (4) Selective Internal Radiation Therapy (SIRT)
Dosimetry providing post-treatment dosimetry using a single time
point of 90Y PET/CT or Bremsstrahlung SPECT/CT as well as treat-
ment planning using a 99mTc-MAA SPECT/CT scan.
QDOSE also features direct comparison of dose estimates for the dif-
ferent available workflows as well as dose prediction for treatment
planning and nuclide comparison.
Results: QDOSE is validated extensively for use in our clinical trials.
Technical validation was performed using synthetically generated
digital phantom data for testing all major functionalities and calcula-
tions. Further workflow validation was performed using a number of
patient datasets. Dose calculations for the spherical model and Voxel
S were validated against the spherical model implemented in the
OLINDA/EXM software [1, 2] using digital phantoms containing
spherical objects. Clinical validation using a variety of clinical data is
done in collaboration with a number of leading internal radionuclide
therapy sites.
Conclusion: QDOSE is a versatile stand-alone, user-friendly, vendor-
neutral dosimetry tool. It offers flexibility allowing for patient-specific
dosimetry in a variety of clinical settings complemented with a
streamlined workflow guidance saving the user time and reducing
user errors.
References
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Aim: The selection and utilization of Yttrium-90 (90Y) microspheres
as a targeted radiotherapeutic is driven by the existing clinical need
to selectively embolize tumor-induced vasculature and deliver high
doses of therapeutic radioactivity to unresectable liver lesions. This is
particularly important when external beam radiation therapy is
deemed impractical. Bremsstrahlung imaging currently serves as the
standard for post-90Y radioembolization assessment but this ap-
proach is limited with poor image quality, poor 90Y-to-background
contrast, and limited capability for post-therapy quantitative dosim-
etry. Although it emits high-energy electrons for therapeutic pur-
poses, 90Y is a theranostic agent given that it also produces a small
fraction of discrete annihilation photons which are imagable with
conventional photomultiplier tube-based PET technology (cPET/CT,
[1]). A recent technological innovation has replaced these conven-
tional photomultiplier tubes in the PET gantry with next-generation,solid-state, digital photon counting PET detectors (digital PET or
dPET) which have Time-of-Flight capability as well as markedly im-
proved timing resolution. Our aim is to assess the clinical impact of
Time-of-Flight on 90Y dPET/CT image quality and post-therapy as-
sessment in patients following liver radioembolization.
Methods: In an ongoing trial, we are using a pre-commercial release
digital PET/CT system (Vereos, Philips Healthcare) to image and assess
90Y microsphere biodistribution in patients with malignant/metastatic
liver lesions after radioembolization therapy. Bremsstrahlung SPECT/CT
imaging was performed within a few hours immediately following
radioembolization with a total image acquisition time of 22 m. Digital
PET imaging was performed in 10 patients at 4 – 50 h following liver
radioembolization with a total image acquisition time of 21 m. PET data
were reconstructed using a 3D OSEM algorithm with and without
Time-of-Flight using a voxel size of 4x4x4 mm3. Image characteristics
and isocontour volumes of 90Y activity were then assessed by matched
comparison using the Intellispace Portal workstation (Philips). In
addition, matched comparison with standard bremsstrahlung SPECT/CT
imaging (Symbia T16, Siemens Healthcare) was performed to fur-
ther assess the practicality and clinical utility of this dPET/CT imaging
approach.
Results: For all patients, dPET images were rated as evaluable and,
when compared with bremsstrahlung SPECT/CT, dPET detection of
90Y radioactivity enabled markedly improved qualitative and volu-
metric assessment of 90Y microsphere biodistribution. In particular,
dPET/CT technology enables post-therapy 90Y imaging with shorter
image acquisition times, improved image quality, contrast, and volu-
metric assessment when compared with standard bSPECT/CT ap-
proaches. Furthermore, Time-of-Flight improved overall image quality
and 90Y-to-background contrast for dPET/CT images when compared
with non-Time-of-Flight dPET but there were no significant differ-
ences in the measured intrahepatic volumes of 90Y activity using
1 % isocontours.
Conclusion: There remains an unmet clinical need to improve quali-
tative and quantitative imaging assessment of 90Y-based radiother-
apies. Current imaging approaches for assessing 90Y in vivo are (1)
challenging in terms of low quality / poorly quantitative brems-
strahlung techniques and (2) potentially disruptive to clinical work-
flows given the long image acquisition times needed for current
cPET techniques. We demonstrate that Time-of-Flight dPET image
quality is superior to the non-Time-of-Flight dPET and standard
bremsstrahlung approaches. Using dPET technology in the future,
we expect that new strategies for 90Y image acquisition as well as
new reconstruction methodologies will facilitate even shorter
image acquisition times with better image quality and more accur-
ate dose quantification in patients treated with existing and new
90Y-based theranostics.
References
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Aim: Individualized dosimetry calculations in external beam- or radio-
nuclide therapy require individual organ masses. Organ segmen-
tation is either done by manual delineation or (semi)-automated
algorithms. The former is dreadfully time consuming and prone to
EJNMMI Research 2016, Volume 6 Suppl 1 Page 5 of 18interobserver errors whereas the later still lacks a golden standard,
especially in case of low image contrast. This talk gives an overview
of the work with active contours (snakes!) as a method for auto-
mated organ segmentation.
Methods: Several versions of active contours were implemented and
tested, e.g. two-dimensional (2D) snakes with a closed curve and a
three-dimensional (3D) where the active contour is represented as a
subdivision surface (SubD). The external force is computed as gradi-
ent vector flow (GVF), i.e. the diffusion of the gradient vectors. In-
house snakes were implemented in Python and SideFX Houdini as
well as existing active contours used, such as the corresponding
function in Adobe After Effects. The rigidity of the active contour was
varied as well as a node network in Houdini implemented, contain-
ing multiple image preprocessing modules. The different snakes were
evaluated on single- and multi- modality patient imaging and com-
pared to manual contouring.
Results: In-house implemented 2D snakes have shown good per-
formance even on low contrast images such as soft tissue organs on
CT without contrast media. However the slice by slice approach faces
difficulties at the top and bottom of organs. This can be improved by
means of 3D SubDs as active contours, though only for specific
image parameters, e.g. Ga68-DOTA PET images of the liver. For CT
data of liver and kidney without contrast media the volume compari-
son between manual and 2D segmentation yielded for the kidney a
mean deviation of 5.16 % and for the liver 3.09 %. The dice coeffi-
cient was on average 0.89 and 0.94 respectively. Regarding 3D seg-
mentation the deviation of the kidney volumes was on average
18.68 % and for the liver 13.02 %, where the dice coefficient was
0.69 and 0.83. Poor resolution of the CT images in z-direction consid-
erably worsens the performance of the 3D active contour. Distracting
forces due to inhomogeneous grey values within the organs and low
contrast to neighbouring structures requires extensive image pre-
processing. Computing the snake’s rigidity has a high impact on the
performance with concave regions.
Conclusion: Even with a versatile tool like active contours and GVF
automated segmentation of soft tissue organs in low contrast re-
mains challenging. A best practice model requires the combination
of elaborate pre-processing, 2D as well as 3D active contours.
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Aim: Transport of drugs by membrane transporters is an important
source of inter-individual variations in drug distribution, drug re-
sponse and of major concern regarding drug-drug interactions. The
investigational third-generation P-glycoprotein (ABCB1) inhibitor tari-
quidar has been used in clinical trials in tumour patients to overcome
multidrug resistance. [11C]Tariquidar is transported at tracer doses
by ABCB1 and breast cancer resistance protein (ABCG2) and can be
used to measure the functional activities of these two transporters atthe blood–brain barrier (BBB) [1]. Carriers of a loss-of-function single nu-
cleotide polymorphism (SNP) in the ABCG2 gene (c.421C > A, Q141K)
have altered plasma pharmacokinetics of ABCG2 substrate drugs
as compared to subjects without the genetic variation [2]. We aim to
assess the effect of this ABCG2 SNP on brain distribution of [11C]
tariquidar.
Methods: Healthy male volunteers were genotyped for the ABCG2
SNP and allocated to a c.421C/C (wild-type) and c.421C/A (heterozy-
gous) group, respectively (n = 5 per group). Subjects underwent two
consecutive 60-min dynamic brain PET scans with [11C]tariquidar, a
first scan after administration of a tracer dose of [11C]tariquidar
(<20 μg) and a second scan during continuous i.v. infusion of un-
labelled tariquidar (3.75 mg/min) in order to inhibit ABCB1 at the
BBB. Atlas based region of interest whole brain grey matter was de-
fined on individual magnetic resonance images and time-activity
curves extracted from the co-registered dynamic PET images. Arterial
blood samples were collected and radioactivity in plasma was mea-
sured in a gamma counter. The ratio of the area under the time-
activity curves (AUC) in brain and plasma (AUCbrain/AUCplasma) was
calculated for the first and second PET scan.
Results: In the first PET scan, no significant differences in AUCbrain/
AUCplasma between the c.421C/C group (mean ± SD = 0.16 ± 0.05)
and the c.421C/A group (0.15 ± 0.02) were observed (p = 0.944, Mann
Whitney-U test). During ABCB1 inhibition (scan two) AUCbrain/AUC-
plasma was not significantly different compared to scan 1 for the c.421C/
C group (AUCbrain/AUCplasma: 0.18 ± 0.07) but significantly increased
for the c.421C/A group (AUCbrain/AUCplasma: 0.23 ± 0.04, +42 ± 8 %%,
p = 0.008, Mann Whitney-U test).
Conclusion: Our data suggest that the effect of the ABCG2 SNP on
brain distribution of the dual ABCB1/ABCG2 substrate [11C]tariquidar
was masked in the first PET scan by the functional compensation be-
tween ABCB1 and ABCG2 at the BBB. Only after ABCB1 inhibition the
ABCG2 SNP was found to have a significant effect on brain distribu-
tion of [11C]tariquidar. To our knowledge, this is the first study show-
ing functional relevance of a polymorphism in the ABCG2 gene on
brain distribution of an ABCG2 substrate. Our findings may have im-
portant implications for treatment of carriers of this SNP with ABCG2
substrate drugs. Moreover, our data highlight the suitability of our
PET protocol to measure ABCG2 function at the human BBB.
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Aim: Overexpression of the ABC-transmembrane transporter P-
glycoprotein (Pgp) at the blood–brain barrier contributes to therapy
refractory temporal lobe (TL) epilepsy [1]. Surgical removal of TL
structures may result in favorable seizure outcome in approximately
60 % of operated cases [2]. Findings from a pilot PET study investi-
gating Pgp function suggest that Pgp overactivity in the TL prior to
surgery may be indicative of optimal postoperative outcome [3].
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scanning before surgery with the Pgp substrate radiotracer (R)-
[11C]verapamil (VPM) in Manchester (n = 6, median age 44, range
18–56 years) and Vienna (n =8, range 33–54 years, dataset from pre-
vious study [3] extended). PET data were acquired on the Siemens
High Resolution Research Tomograph in Manchester and on the GE
Advance PET scanner in Vienna. Atlas based regions of interest were
defined in the ipsilateral TL on individual magnetic resonance images
and time-activity curves extracted from the co-registered dynamic
PET images [1,3]. Metabolite corrected arterial input functions were
used to estimate the net influx of VPM from plasma into brain (K1)
from the first 10 min of PET data [1,3]. Clinical follow-up data on seiz-
ure activity and anti-epileptic medication were available for 4 ±
1 years for Manchester and 6 ± 1 years for Vienna patients. Ranking
of surgery outcome was done according to the modified Wieser’s
classification (best outcome assigned rank 1) [3].
Results: Correlation of VPM K1 values in ipsilateral TL with surgery
outcome rank in individual patients was highly positive (Pearson r =
0.7573, p = 0.0017, n = 14). Patients with the highest Pgp activity
(lowest K1 values) before surgery showed optimal surgery outcome
(seizure and medication free) whereas those with the lowest Pgp ac-
tivity continued to have seizures and to take medication even after
surgery. Findings were consistent for both centres.
Conclusion: Pooled analysis of pre-operative VPM PET data consist-
ently predicted outcome after TL epilepsy surgery in two centres,
confirming findings from a previous pilot study. PET measurement of
Pgp function should be further evaluated as an imaging biomarker
for the prediction of TL epilepsy surgery outcome.
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Aim: The melanin concentrating hormone (MCH) is a cyclic neuro-
peptide which is predominantly expressed in the lateral hypothal-
amus and zona incerta [1, 2]. The biological effect is mediated by
two G-protein coupled receptors (GPCR), the MCH receptor 1 and 2
(MCHR1 and MCHR2) [3]. Changes in the expression of the MCHR1
have been shown to be involved in a variety of pathologies, such as
depression and anxiety disorders and are related to the central
mechanisms of obesity [4, 5]. In this regard, the preparation and first
in-vitro studies of [18F]FE@SNAP and [11C]SNAP-7941, as potential
positron emission tomography (PET) radiotracers for the visualization
of the MCHR1, were performed successfully [6, 7, 8, 9]. Based on
the preceding results the present present study aimed at a fur-
ther in-vitro and in-vivo evaluation of [18F]FE@SNAP and its structurally
closed non radioactive derivatives FE@SNAP, SNAP-7941 and (+)-SNAP-
7941 to provide high-impact predictive values for a further translation
into clinical PET imaging.Methods: In-vitro: Binding affinity of SNAP-7941, (S)-SNAP-7941,
FE@SNAP and MCH were determined in competitive centrifuga-
tion binding studies with [125I]MCH using chinese hamster ovary
(CHO-K1) membranes stably expressing the human MCHR1. Kinetic
real-time binding studies with [18F]FE@SNAP were conducted on ad-
herent CHO-K1 cells stably expressing the human MCHR1 and MCHR2.
Experiments on blank CHO-K1 cells were performed to determine un-
specific binding.
In-vivo: Small-animal μPET/CT and μMRI imaging was performed in
naïve male Sprague Dawley rats (HIM:OFA; 438 ± 42 g). The rats were
anesthetized with isoflurane/oxygen (1.5 % / 0.8 mL) and [18F]FE@
SNAP was administered through the lateral tail vein (47.8 ± 1 MBq; SA:
19.7 ± 6GBq/μmol). Radiotracer uptake in the brain (SUV; g/mL) was de-
termined under i) baseline conditions, ii) blocking with 15 mg/kg
SNAP-7941 and iii) blocking with 15 mg/kg tariquidar. After the
imaging the rats were sacrificed, the organs were harvested and
subjected to radioactivity measurements. The resulting values
were expressed as percent injected dose per gram tissue (%ID/g).
Results: Binding studies revealed Ki values of 6.25 ± 2.26nM (SNAP-
7941; n = 3), 7.34 ± 0.57nM ((+)-SNAP-7941; n = 3), 20.74 ± 3.62nM
(FE@SNAP; n = 3) and 0.16 ± 0.06nM (MCH; n = 3) respectively. Kinetic
binding studies of [18F]FE@SNAP showed observed association rate
constants of 0.069 ± 0.003 M-1 · min-1 (n = 3) to hMCHR1 and 0.063 ±
0.004 M-1 · min-1(n = 3) to hMCHR2. Kinetic binding studies with
blank CHO-K1 cells revealed no radiotracer uptake & low unspecific
binding (n = 3). In-vivo small animal experiments evinced a brain up-
take of 0.28 ± 0.05 g/mL (baseline group; n = 5), 0.28 ± 0.03 g/mL
(blocking with SNAP-7941; n = 2) and 0.48 ± 0.17 g/mL (blocking with
tariquidar, n = 2).
Conclusion: The binding affinity of SNAP-7941 and the (S)-enantio-
mer revealed comparable results, both in a low nanomolar range. As
opposed to this, FE@SNAP evinced a significantly lower Ki. Real-time
binding studies of [18F]FE@SNAP showed no differences in the bind-
ing kinetics between the receptor subtypes. Specific uptake of
[18F]FE@SNAP in the rat brain seems to be prevented by p-gp and/
or BCRP, since small animal μPET experiments revealed a 2–2.5 fold
increased brain uptake after p-gp/BCRP inhibition with tariquidar.
Further in-vivo investigations with respect to peripheral MCHR1 ex-
pression of healthy, obese and diabetic rats need to be performed to
further proof the applicability of the MCHR1 concept.
References
[1] Kawauchi, et al. (1983) Nature. 305:321–3.
[2] Bittencourt et al. (1992) J Comp Neurol. 319(2):218–45.
[3] Sailer et al. (2001) Proc Nat Acad Sci USA. 98:7564–7569.
[4] Smith et al. (2006) Neuropsychopharmacology. 31(6):1135–45.
[5] Ito et al. (2009) Eur J Pharmacol. 624(1–3):77–83.
[6] Philippe et al. (2012) Bioorg Med Chem. 20(19):5936–40.
[7] Philippe et al. (2012 Appl Radiat Isot. 70(10):2287–94.
[8] Philippe et al. (2013) Sci Pharm. 81(3):625–39.
[9] Philippe et al. (2013) Nuc Med Biol. 40(7):919–25.
A14
Reducing time in quality control leads to higher specific
radioactivity of short-lived radiotracers
L Nics1, B Steiner1, M Hacker1, M Mitterhauser2, W Wadsak1
1Department of Biomedical Imaging and Image guided Therapy, Division
of Nuclear Medicine, Medical University of Vienna, Vienna, Austria; 2Ludwig
Boltzmann Institute for Applied Diagnostics, Vienna, Austria
EJNMMI Research 2016, 6(Suppl 1):A14
Aim: Time plays a pivotal role in the preparation of radiopharmaceu-
ticals (RP) labeled with short-lived radionuclides (e.g. carbon-11,
nitrogen-13, gallium-68). In particular, it has to be taken into account
that radioactive decay starts to reduce available activity as soon as
the produced radionuclide is delivered to the synthesis unit. This is
also true for the specific radioactivity (SA; activity per mass unit)
which is of significant importance for radiotracers targeting saturable
targets such as transporters or receptors. This process lasts until ap-
plication of the RP after passing the quality control (QC) and final re-
lease of the product. So far, time reduction was mostly implemented
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contrast, QC procedures were not considered to a full extent in that
perspective. Determination of radiochemical purity and SA normally
requires the use of high performance liquid chromatography (HPLC)
which is also the most time-consuming step in the QC procedure. Re-
cently, Nakao et al. [1] suggested a method involving hybrid (ultra-)HPLC
((U)HPLC) to shorten run times. Hence, aim of this work was to imple-
ment fast HPLC for [11C]DASB and (+)-[11C]PHNO to enhance specific
radioactivity.
Methods: [11C]DASB and (+)-[11C]PHNO were prepared according to
methods described in detail elsewhere. [2,3] All analytical HPLC ana-
lyses were performed on an Agilent 1260 system equipped with a
quaternary pump, a multi wavelength UV-detector, a manual injector
and a radiodetector and controlling software. HPLC column was a
Waters X-bridge BEH Shield RP-18 (4.6 x 50 mm, 2.5 μm, 130 Å). In-
jection volume was 5 μL. For [11C]DASB, the following conditions
were applied: wavelength 254 nm; Flow rate 1.0 mL/min; Mobile
phase: A: 50 mM ammonia phosphate buffer, pH 9.3; B: 90 % ACN /
10 % aqua dest. (v/v); Isocratic: 40 % A / 60 % B. For (+)-[11C]PHNO,
the following conditions were applied: wavelength 280 nm; Flow rate
1.6 mL/min (0-30”), then 1.0 mL/min; Mobile phase: A: 100 mM ammo-
nia phosphate buffer, pH 2.1 including 5 mM sodium-1-octasulfonate;
B: 90 % ACN / 10 % aqua dest. (v/v); C: Aqua purificata (HPLC grade); D:
50 mM ammonia phosphate buffer, pH 9.3; Isocratic: 33 % A / 20 % B /
14 % C / 33 % D.
Results: For [11C]DASB, total HPLC run time was 1.0 min; precursor
MASB eluted after 23 sec, DASB eluted after 55 sec, respectively. For
(+)-[11C]PHNO, total HPLC run time was 1.1 min; precursor (+)-HNO
eluted after 27 sec, PHNO eluted after 61 sec, respectively. Hence, a
reduction of >5 min was achieved for both radiotracers which equals
an increase in available activity and SA of more than 15 %.
Conclusion: This work demonstrates the importance of optimizing
QC procedures such as HPLC to reduce overall time before release
and application of short-lived radiopharmaceuticals. An increase in
SA of >15 % was observed when implanting an optimized chromato-
graphic protocol for [11C]DASB and (+)-[11C]PHNO.
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Aim: Erlotinib is a tyrosine kinase inhibitor of the epidermal growth
factor receptor (EGFR) used to treat patients with non-small cell lung
cancer (NSCLC). NSCLC patients with activating mutations (e.g. exon
19 deletion) in the EGFR gene have increased response rates to erlo-
tinib treatment compared to patients with wild-type EGFR. However,
patients with activating EGFR mutations eventually develop resist-
ance to erlotinib caused by secondary mutations (e.g. T790M). 11C-
erlotinib PET signal was found to be higher in NSCLC tumors with an
activating EGFR mutation than in tumors with wild-type EGFR [1]. It is
however, not known if 11C-erlotinib PET will be able to distinguish
tumors with secondary resistance causing mutations from erlotinib-
sensitive tumors. Aim of this study was to measure in vitro 11C-
erlotinib binding in erlotinib-sensitive and erlotinib-resistance can-
cer cell lines.
Methods: One glioblastoma (U-87 MG) and four NSCLC (erlotinib-sen-
sitive HCC827, erlotinib-resistant HCC827, gefitinib-resistant HCC827,
and erlotinib-resistant HCC827 with a secondary EGFR mutation) celllines were incubated with 11C-erlotinib up to 60 min. In a second set
of experiments cell lines were pretreated with unlabeled erlotinib or
different P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP) inhibitors (elacridar, Ko143, tariquidar) and then incubated
with 11C-erlotinib for 30 min. Retained radioactivity in the cells was
measured in a gamma counter and normalized to cell count.
Results: Uptake of 11C-erlotinib was significantly lower in U-87 MG
cells compared to all NSCLC cell lines. No significant differences were
observed in the uptake of 11C-erlotinib between the four NSCLC cell
lines. In all NSCLC cell lines 11C-erlotinib uptake was significantly re-
duced following pretreatment with unlabeled erlotinib, which was
not the case for U-87 MG cells. Pretreatment with elacridar, Ko143 or
tariquidar had no effect on 11C-erlotinib uptake in all tested cell
lines.
Conclusion: We found significantly lower uptake of 11C-erlotinib in
U-87 MG cells with wild-type EGFR compared to all NSCLC cell lines,
which had activating EGFR mutations. No significant differences in
11C-erlotinib uptake were observed between erlotinib-sensitive,
erlotinib-resistant, and gefitinib-resistant NSCLC cell lines. In all
NSCLC cell lines a significant reduction of 11C-erlotinib uptake after
pretreatment with unlabeled erlotinib was found, suggesting specific
binding to EGFR. Efflux of 11C-erlotinib by P-gp and BCRP was not
evident in any of the studied cell lines. Taken together, our findings
suggest that 11C-erlotinib PET may be suitable to distinguish wild-type
EGFR from EGFR with activating mutations, but unsuitable to identify
secondary resistance causing mutations. To further extend our in vitro
findings, PET studies will be carried out in tumor-xenografted nude
mice using erlotinib-resistant and erlotinib-sensitive NSCLC cell lines.
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Aim: Multidrug resistance-associated protein 1 (MRP1) is a membrane
transporter expressed at the blood–brain and blood-cerebrospinal fluid
barriers, which has been suggested to play a role in beta-amyloid
clearance from brain into blood [1]. 7-[11C]methyl-6-bromopurine
([11C]7m6BP) is a novel PET tracer to measure MRP1 function in the
brain [2]. Visualization of MRP1 function with [11C]7m6BP is based on a
pro-drug approach: the probe enters the brain by passive diffusion and
gets rapidly converted into its glutathione conjugate S-(6-(7-methylpur-
inyl))glutathione ([11C]PSG), which is effluxed from the brain by MRP1.
Aim of this work was to establish the radiosynthesis of [11C]7m6BP in
our lab and perform a first PET evaluation of [11C]7m6BP in wild-type
and Mrp1(−/−) mice.
Methods: [11C]7m6BP was produced by N-methylation of commer-
cially available 6-bromopurine using [11C]methyl triflate in a Tracer-
lab FX C Pro synthesis module with slight modifications compared to
the literature [2]. Female C57BL6 wild-type and Mrp1(−/−) mice aged
153–211 days (n = 6 per group) underwent 90 min dynamic [11C]
7m6BP PET scans. Whole-brain time-activity curves were obtained
and the efflux rate constant (keff) of radioactivity from brain was cal-
culated using data from 17.5-80 min after radiotracer injection. In
separate groups of wild-type and Mrp1(−/−) mice radiolabelled metab-
olites of [11C]7m6BP were analyzed by radio-thin layer chromatog-
raphy (TLC) in plasma and brain at 15 and 60 min after radiotracer
injection (n = 3 per group and time point).
Results: [11C]7m6BP was obtained in a radiochemical yield of 16.8 ±
1.7 % (n = 12) (based on [11C]methyl triflate, decay-corrected) in a
total synthesis time of 29 min. Radiochemical purity was >98 % and
EJNMMI Research 2016, Volume 6 Suppl 1 Page 8 of 18specific activity at end of synthesis was 428 ± 232 GBq/μmol (n = 8).
Radio-TLC analysis showed that at 15 min after radiotracer injection
all radioactivity in the brain consisted of the desired glutathione con-
jugate [11C]PSG. Whole brain time-activity curves were characterized
by a rapid washout of radioactivity in wild-type mice and a pro-
longed retention of radioactivity in Mrp1(−/−) mice. Brain efflux rate
constant (keff) of radioactivity was significantly (p < 0.05, t-test) re-
duced in Mrp1(−/−) compared to wild-type mice ((keff (h-1): wild-
type: 1.29 ± 0.33; Mrp1(−/−): 0.25 ± 0.03).
Conclusion: We were able to set up the automated radiosynthesis of
[11C]7m6BP in practical radiochemical yield and high radiochemical
purity. A first PET evaluation suggests that [11C]7m6BP is suitable to
measure Mrp1 function in mouse brain.
Funding: FWF-DACH project I 1609-B24.
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Aim: Bioorthogonal ligations are capable of forming covalent bonds
in highly complex environments. Since their introduction in 2000
their potential to be used in pretargeting experiments has drawn
much attention in the field of (PET-) imaging. (1) Pretargeting means
splitting of the tracing compound into a marker, which is enriched in
target tissue and a radiolabeled pull down reagent (PDR). By using
such an approach, longer periods of time for enrichment of the
marker compound can be provided, which is crucial for PET measure-
ments with high contrast of target to normal tissue. After this labeling
step the PDR is injected, which should react with the trapped marker in
a bioorthogonal way. This would allow the use of short living radioiso-
topes in PET imaging of slow accumulating markers and leads to en-
hanced signal-to-noise ratios and lower radioactivity doses.
The most prominent bioorthogonal reaction, the strain-promoted
azide alkyne cycloaddition (SPAAC), has been used in a wide variety
of applications in chemical biology and biomedicine. (2) This reaction
features the Huisgen-Cycloaddition between an azide and a strained
cycloalkyne to form triazoles. SPAAC has already been used in pretar-
geted PET imaging featuring short lived 18F as radionuclide by Lee
et al. (3) although they do not report about biodistribution and sta-
bility of the azide-labeled pull-down-reagent.
Aim of this work was the synthesis and in vivo evaluation of 18F la-
beled azidoglucoses as pull-down reagent for pretargeted PET imaging
using SPAAC as bioorthogonal ligation. Using glucose derivatives as
PDRs has several advantages, such as good and fast biodistribution and
possible active uptake into cells by glucose transporters. Blocking of
the 6 position with 18F will prevent phosphorylation and therefore
trapping in cells can only occur after bioorthogonal reaction. Two dif-
ferent isomers were evaluated, both containing 18F at position 6
while either 1-OH (18F-AzFDG16) or 2-OH (18F-AzFDG26) was dis-
placed against an azide group.
Methods: Precursors for radiosynthesis were prepared in 4 and 3 steps
respectively starting from commercially available material. Radiosynth-
esis were carried out by nucleophilic displacement of a nosylate by
18F-Fluorine followed by alkaline hydrolysis on a tC18 SepPak cartrid-
geand formulation in saline solution.
In vivo studies were performed by administration of 18F labeled azido-
glucoses to female BALB/c mice followed by dynamic PET imaging (n =
6 for 18F-AzFDG16, n = 4 for 18F-AzFDG26) for 120 min. At the end of
the imaging experiment the mice were sacrificed and harvested urine
and plasma samples were screened for radiometabolites using radio-thin-layer-chromatography (TLC). Selected organs were withdrawn and
gamma counted to validate data from the last PET time frame.
Results: 18F-AzFDG16 and 18F-AzFDG26 were obtained in good yields
and high radiochemical purity. PET Imaging revealed a very homo-
genous and fast biodistribution of both substances in all regions in the
body excluding the brain, as well as rapid renal excretion. Furthermore,
PET imaging revealed no significant extent of in vivo defluorination of
both PDRs, since no enhanced radioactivity uptake in bone was ob-
served. High Stability of these reagents was also confirmed by metabol-
ite analysis (radio-TLC).
Conclusion: Fluoroazidoglucoses have proven to be promising click
agents for in vivo application applying SPAAC, due to homogenous
and fast biodistribution, high metabolic stability as well as fast excre-
tion. Synthesis and evaluation of further derivatives as well as in vivo
click experiments are currently under investigation.
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Aim: Slow tracer accumulation of imaging probes can be circum-
vented by pretargeting using bioorthogonal ligations. These fast and
biocompatible “click” reactions are capable of forming a covalent
linkage between a pre-administered marker and a labeled pull down
reagent (PDR) in vivo. Due to particular high ligation rates the inverse
electron demand Diels-Alder reaction (IEDDA) of strained dienophiles
with 1,2,4,5-tetrazines (Tz) has gained interest in nuclear medicine.
Until recently, only few radiolabeled tetrazines mainly based on
radiometals and bulky chelating agents have been reported. How-
ever, the use of short-lived PET isotopes (18F, 11C) with favorable
decay characteristics and high specific activity was limited due to
chemical stability and reactivity restrictions.
Within this contribution an overview will be given describing the
concept of bioorthogonal PET imaging. Furthermore the develop-
ment of various low molecular weight radiotetrazine probes labeled
with fluorine-18 and carbon-11 will be presented.
Methods: In silico methods were used to investigate IEDDA ligation
reactivity prior to synthesis. Tetrazines were synthesized using metal
catalysis, and precursor substances (tosylates for 18F-radiochemistry,
primary amines for 11C-radiochemistry) were labeled in good radio-
chemical yields avoiding the use of prosthetic groups. Radiochemical
purity was assessed by radio-HPLC and TLC, and the identity of labeled
PDRs was verified by co-injecton with non-radioactive reference mate-
rials. Biodistribution and excretion kinetics were investigated by admin-
istration into female BALB/c mice and whole body dynamic PET/MR
scanning for 120 min (18F) or 60 min (11C). Furthermore blood and
urine samples were analyzed for radiometabolites and gamma count-
ing of selected organs was conducted to confirm PET results.
Results: A set of several tetrazine probes labeled with fluorine-18 and
carbon-11 was developed. The compounds 3-(3-[18F]-Fluoropropyl)-6-
methyl-1,2,4,5-tetrazine and N-[11C]-methyl-1-(6-methyl-1,2,4,5-tetrazin-
3-yl)methanamine exhibit high metabolic stability, homogenous biodis-
tribution (including the brain) and fast excretion making them valuable
candidates to be used as PDR in pretargeted PET applications. Other
18F-tetrazines were found to be metabolically unstable but still proved
highly valuable to be used for rapid radiolabeling of dienophile-tagged
biomolecules.
EJNMMI Research 2016, Volume 6 Suppl 1 Page 9 of 18Conclusion: To this end a selection of promising bioorthogonal tools
is available that should allow for pretargeted PET imaging of slow ac-
cumulating probes as well as rapid radiolabeling in highly complex
(biological) matrices.
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Aim: The human adenosine-3-receptor (hA3R) is highly expressed in
various tumor cell lines. (1) [18F]FE@SUPPY, a hA3R antagonist with
high affinity and selectivity, was developed as a potential PET-tracer
for tumor imaging. The preclinical evaluation of this tracer aimed at
the determination of the specific binding to tumor tissue compared
to healthy tissue. Moreover, a further aim was the identification of a
suitable human tumor cell line for transplantation into immunocom-
promised mice (xenograft model).
Methods: Characterization of tumor cell lines regarding hA3R protein
expression was conducted using Western Blot, flow cytometry and im-
munofluorescent staining. Specific binding of [18F]FE@SUPPY was in-
vestigated in autoradiography experiments using colorectal carcinoma
tissue and healthy mucosa tissue derived from the same patient.
Results: The hA3R protein was detected via Western Blot in different
tumor cell lines (A431, BT474, HT29 and PC3). Flow cytometry experi-
ments revealed mean fluorescence intensity values (ΔMFI) of 113.6 ±
52 for A431, 53.6 ± 22 for HT29, 46.13 ± 18For BT474 and 49.1 ± 31
for PC3 cells, respectively (n ≥ 3). [18F]FE@SUPPY showed increased
binding to tumor tissue (9.18 ± 2.38 fmol/mm2) compared to healthy
tissue (3.50 ± 0.95 fmol/mm2).
Conclusion: Autoradiography experiments revealed a 2.6 fold in-
creased uptake of [18F]FE@SUPPY in colorectal carcinoma tissue
compared to healthy mucosa. The tumor cell lines HT29 and A431
showed the highest expression of the hA3R and therefore will be
used for the planned xenograft model.
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Aim: In recent years the concept of pretargeted PET imaging using
bioorthogonal chemistry has drawn a lot of attention as it allows im-
aging of slow accumulating probes with short-lived radionuclides
leading to enhanced signal-to-noise ratios and lower patient radi-
ation doses. The underlying idea is based on a two-step approachthat includes administration of a target tissue (e.g. tumor) sensitive
probe followed by a radiolabeled pull down reagent (PDR). The
probe and PDR will ligate in vivo via a bioorthogonal reaction, which
does not interfere with native biochemical processes and exhibits
high reaction rates.
The aim of this work was to investigate the biostability and -distribu-
tion of various low molecular-weight [18F]-fluoroalkylazides to evalu-
ate their potential as PDRs in the bioorthogonal copper-free-click
reaction (CFC) between azides and cyclooctynes.
Methods: Precursor materials for [18F]-fluoroalkylazides were ob-
tained via straightforward synthetic chemistry using commercially
available reagents. Radiolabeling of an improved precursor (crystal-
line instead of liquid) was achieved in high yields and short reaction
times using the Kryptofix 222/K2CO3 method. The identity of target
compounds was verified by comparison of HPLC retention times with
non-radioactive reference materials.
In vivo biodistribution studies were performed by administration of
[18F]-radiolabeled fluoroalkylazides to female BALB/c mice and sub-
sequent dynamic PET/MR imaging over a period of two hours. At the
end of the experiment the mice were sacrificed to allow HPLC ana-
lysis for radiolabeled metabolites of plasma and urine samples. Se-
lected organs were withdrawn and checked for radioactivity.
Results: Even though one of the investigated compounds, [18F]2-
fluoroethylazide (18F-FEAz), was reported by Evans et al. [1] to show
promising properties to be used as PDR, the conducted experiments
indicated rapid metabolization and high bone uptake. Metabolite
analysis confirmed degradation and formation of free 18F-fluoride.
Hence, aiming for improved metabolic stability, structural modifica-
tions led to the compounds 18F-FPAz and 18F-2-FPA, which were
also labeled in excellent yields. Both novel compounds are highly
valuable as prosthetic groups for “click” radiolabeling due to im-
proved accessibility of cold reference materials (as compared to
FEAz). Unfortunately 18F-FPAz and 18F-2-FPA did not show improved
in vivo stability, thus limiting their use as in vivo click agent (PDR) for
pretargeted PET imaging.
Conclusion: In the course of this work we were able to prepare a
novel set of [18F]-fluoroalkylazides, whose cold reference materials
exhibit favorable physical properties and accessibility compared to
already reported [18F]2-fluoroethylazide. Even though our studies
showed that the synthesized compounds are not suitable for in vivo
imaging, they seem to be attractive candidates for application in
rapid [18F]-radiolabeling, which is currently under investigation.
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Aim: In radiochemistry, main focus is set on time efficiency, auto-
mated syntheses as well as high chemical conversion. To meet these
requirements, microfluidic devices have been tested for downsizing
the precursor amount of already established radiosyntheses during
the last years [1]. This approach usually enables an enhanced conver-
sion due to a high surface-to-volume ratio [2]. Microfluidic devices
have scarcely been tested for Ga-68-radiolabeling so far [3]. The aim
of this study was to test the feasibility of using a fully automated
microfluidic system containing a flow-through reactor for the radio-
synthesis of Ga-68-PSMA-HBED-CC.
EJNMMI Research 2016, Volume 6 Suppl 1 Page 10 of 18Methods: Ga-68-radiolabeling of PSMA-HBED-CC (ABX, GMP grade)
was performed using an Advion NanoTek LF system containing a
flow-through microreactor that consists of a silica capillary (l = 2 m,
Ø100 μm, V = 15.6 μL). 68Ga3+ was obtained from a Ge-68/Ga-68
generator (3.7 GBq; Obninsk) and the eluate was collected according
to a fractionized protocol. Roughly 400 μL of the peak activity were
loaded into the storage loop within the NanoTek system and aliquots
of different volumes were used for subsequent reactions. For op-
timization of PSMA-HBED-CC radiolabeling different flowrates (i.e. 30,
50, 80 μL/min), reaction volumes (40–740 μL), temperatures (25-150 °C)
and precursor concentrations (0.2-3 nmol) were evaluated. NaOAc- and
HEPES-solutions (1.5 M) were used for pH adjustment.
Results: Ga-68-radiolabeling of PSMA-HBED-CC (ABX, GMP grade)
was performed using an Advion NanoTek LF system containing a
flow-through microreactor that consists of a silica capillary (l = 2 m,
Ø100 μm, V = 15.6 μL). 68Ga3+ was obtained from a Ge-68/Ga-68
generator (3.7 GBq; Obninsk) and the eluate was collected according
to a fractionized protocol. Roughly 400 μL of the peak activity were
loaded into the storage loop within the NanoTek system and aliquots
of different volumes were used for subsequent reactions. For
optimization of PSMA-HBED-CC radiolabeling different flowrates (i.e. 30,
50, 80 μL/min), reaction volumes (40–740 μL), temperatures (25-150 °C)
and precursor concentrations (0.2-3 nmol) were evaluated. NaOAc- and
HEPES-solutions (1.5 M) were used for pH adjustment.
Conclusion: To the best of our knowledge, we were able to demon-
strate for the first time the successful microfluidic Ga-68-radiolabeling
of PSMA-HBED-CC. Moreover, we observed that radiochemical con-
version can be further enhanced, when purging the system with all
reagents prior to syntheses. This proof-of-principle might lead to in-
creased availability of Ga-68-tracers following the dose-on-demand
principle.
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Aim: 24-nor-ursodeoxycholic acid (norUDCA) is a novel therapeutic
approach to cholestatic liver diseases. In mouse models of cholestasis
norUDCA induces basolateral multidrug resistance-associated pro-
teins 4 and 3 (Mrp4, Mrp3) in hepatocytes, which provide alternative
escape routes for bile acids accumulating during cholestasis but
could also result in altered hepatic disposition of concomitantly ad-
ministered substrate drugs.
Methods: We used PET imaging to study the influence of norUDCA
on hepatic disposition of the model Mrp4 substrate [18F]ciprofloxa-
cin in wild-type and Mdr2(−/−) mice, a model of cholestasis. Animals
underwent 90 min dynamic [18F]ciprofloxacin PET scans at baseline
and after 5 days of oral norUDCA treatment.
Results: Following norUDCA treatment, liver-to-blood area under the
curve ratio of [18F]ciprofloxacin was significantly decreased compared
to baseline, both in wild-type (−34.0 ± 2.1 %) and Mdr2(−/−) mice
(−20.5 ± 6.0 %). [18F]Ciprofloxacin uptake clearance from blood into
liver was reduced by −17.1 ± 9.0 % in wild-type and by −20.1 ± 7.3 % in
Mdr2(−/−) mice. Real-time PCR analysis showed significant increases in
hepatic Mrp4 and Mrp3 mRNA following norUDCA. Transport experi-
ments in OATP1B1-, OATP1B3- and OATP2B1-transfected cells revealedweak transport of [14C]ciprofloxacin by OATP1B3 and OATP2B1 and no
inhibition by norUDCA.
Conclusion: Our data suggest that changes in hepatic [18F]ciproflox-
acin disposition in mice following norUDCA treatment were caused
by induction of basolateral Mrp4 in hepatocytes. If norUDCA also in-
duces basolateral ABC transporters in humans, this could potentially
lead to transporter-mediated drug-drug interactions for drugs which
are substrates of these transporters and for which the liver is the
main clearance and/or therapeutic target organ. Finally, we speculate
that [18F]ciprofloxacin PET may allow to functionally visualize the
pharmacologically induced adaptive basolateral ABC transporter re-
sponse in cholestatic disorders.
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Aim: Production of 18F-flumazenil from 2-nitroflumazenil under GMP
conditions is primarily performed with manipulators or custom built
radiosynthesis modules with fixed components, as the use of N,N-
dimethylformamide (DMF) at 160 °C prohibits the use of commonly
available disposable cassettes. Cassettes for the GE TRACERlab MXFDG
synthesis modules are commercially available in different materials.
ROTEM Industries and GE Healthcare use polysulfone as the main com-
ponent, and it is known that this polymer is not compatible with DMF.
Cassettes from ABX are reportedly more chemical resistant, with poly-
propylene as its main constituent. The aim of this work was to establish
a robust automated radiosynthesis procedure for 18F-flumazenil on the
GE TRACERlab MXFDG, where staff previously trained on the same
equipment can easily perform the radiosynthesis.
Methods: Fragments of the ABX FDG cassette was exposed for 1 or
24 h to various solvents including acetonitrile and DMF at room
temperature (RT) or 60 °C to assess its chemical resistance. A new
synthesis sequence was written for the GE TRACERlab MXFDG. A
non-radioactive test run was performed with the ABX FDG cassette,
and radiosynthesis was carried out with the cassette components re-
placed by chemically resistance manifolds (ABX).
Results: Incubation of the PP ABX FDG cassette fragments in aceto-
nitrile at RT showed no macroscopic influence on the polymer while
the fragment became soft and mouldable at 60 °C. Visible changes
occurred after 1 h incubation with DMF, with the polymer having
completely dissolved after 24 h, regardless of temperature. To verify
the implication of these results on a 1 h radiosynthesis, a test run
was performed using the same cassette material and synthesis condi-
tions without radioactivity. Parts of the manifold was found to have
cracked, and a valve blockade was observed due to polymer melting.
Radiosynthesis was carried out with the manifolds replaced by chem-
ically resistant ones, and 18F-flumazenil was successfully obtained in
4 % decay corrected yield.
Conclusion: Disposable cassettes assembled with chemically resist-
ant manifolds is a requirement for the automated synthesis of 18F-
flumazenil from 2-nitroflumazenil using the GE TRACERlab MXFDG
synthesis module. Neither reagent kits nor program sequences are
hitherto commercially available, but GMP grade production can
nonetheless be successfully carried out with modifications on exist-
ing equipment.
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EJNMMI Research 2016, Volume 6 Suppl 1 Page 11 of 18Aim: Over the last years, peptide receptor radiotherapy (PRRT) using
177Lu in the treatment of neuroendocrine tumours (NET) and pros-
tate cancer (PCa) has become a major issue in nuclear medicine.
Consequently, the safe and reliable production and quality control of
therapeutic amounts of suitable radiopharmaceuticals, i.e. 177Lu-
DOTA-TATE and 177Lu-HA-DOTA-TATE (“high affinity DOTA-TATE”)
for NET-treatment as well as 177Lu-DOTA-PSMA (PSMA-617) against
PCa, had to be established and optimized. Similarities and differences
in the set-up are reported in this work.
Methods: 177Lu-radiolabelling was performed using the cassette-
based ModularLab PharmTracer® synthesizer (EZAG, Berlin, Germany)
and starting activities of 9.0-19.0GBq 177LuCl3 (no-carrier-added; itg,
Munich, Germany) in 0.5 ml 0.04 M HCl. For the somatostatin ana-
logues, approximately 250-500 μg of DOTA-TATE (ABX, Radeberg,
Germany) or HA-DOTA-TATE (PiChem, Graz, Austria) – calculated as
1 μg peptide/40 MBq 177LuCl3 + 10 % peptide, dissolved in deion-
ized water – were reacted at 80 °C/20 min in 0.57 M ascorbate buffer,
pH 4.5. For DOTA-PSMA (ABX), approximately 130-270 μg of DOTA-
PSMA – 1 μg peptide/65 MBq 177LuCl3 peptide, dissolved in Ethanol
(48 %) – was reacted at 90 °C/10 min in 0.57 M ascorbate buffer,
pH 4.5 and with 200 μl Ethanol (96 %). All precursors were of GMP
quality. Crude 177Lu-DOTA-TATE/-HA-DOTA-TATE was purified on a
C18 SPE cartridge without any further dilution, whereas 177Lu-DOTA-
PSMA was first prediluted with 2 ml saline (0.9 %), before purification
on a C18-SepPak by washing with 2 ml saline (0.9 %). Elution was
done with 2 ml ethanol (48 %) and the product was transferred and
0.22 μm-filtrated to the product vial together with 16 ml saline
(0.9 %). To all 177Lu-DOTA-peptide-formulations 0.5-1.2 ml DTPA
(3 mg/ml) was added. Full radiopharmaceutical quality control was
performed for all 177Lu-peptide formulations (e.g. radio-TLC-, HPLC-,
pH-, sterility- and apyrogenicity testing).
Results: 177Lu-labelling of DOTA-coupled somatostatin analogues
was introduced at the Medical University / General Hospital of Vienna
in 2010 and 177Lu-DOTA-TATE- syntheses were performed until 2015
(n = 109). Due to legal restrictions in the availability of DOTA-TATE
precursor we recently switched to the use of 177Lu-HA-DOTA-TATE
(n = 13, so far). Also this year, the production of 177Lu-DOTA-PSMA
was implemented (n = 14, so far). All 177Lu-productions took about
45 min (synthesis, including conditioning, purification and sterile fil-
tration) plus 120 min for preparation of the devices plus 60 min for
QC. The synthesis failure rate was 99 %. All 177Lu-lots were sterile
and endotoxins were <1EU/ml. The HA-DOTA-TATE-precursor was
somewhat less soluble than DOTA-TATE. 177Lu-DOTA-PSMA showed
a slightly different chromatographic behaviour in TLC and HPLC
compared to 177Lu-DOTA-TATE and 177Lu-HA-DOTA-TATE.
Conclusion: Both the somatostatin analogues 177Lu-DOTA-TATE and
177Lu-HA-DOTA-TATE for NET-treatment but also 177Lu-DOTA-PSMA for
treatment of PCa could be safely produced in activities up to <16GBq
(2 therapeutic doses) and excellent quality under observation of proper
radioprotection and radioactive waste management. Differences in the
preparations were of minor concern. Set-up for the 3 different radiother-
apeutics could be easily adapted.
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Aim: PSMA is a most promising ligand for imaging and therapy of
prostate cancer lesions. Ever since the DOTA conjugated ligand
PSMA-617 is known, the DOTA ligand can be labelled with a broad
range of radionuclides (1). Our aim was, on the one hand, to estab-
lish labelling of 68Ga-PSMA-617 for PET diagnosis, and on the con-
trary 177Lu-PSMA-617 for therapy. Both should be compliant to the
GMP preparation methodology.
Methods: The ligand PSMA-617 was purchased from ABX. 68Ga-PSMA-
617 was prepared with a cationic purified (5 M NaCl, SCX PS-H+)
68GaCl3 (1.8 GBq Generator, IThemba). The labelling of 20 μg PSMA-
617 was performed in HEPES solution at 125 °C/6 min. The crudemixture was purified by C18 SPE. For 177Lu-PSMA-617, 200 μg PSMA-
617 was labelled with 10 GBq 177LuCl3 (ITG) in sodium acetate/ascor-
bate buffer at 100 °C/20 min. Then, the reaction mixture was diluted
and sterile filtrated without further purification. Both kinds of synthesis
was carried out with a Scintomics GRP synthesizer, sterile single use
cassettes and the standard synthesis sequences for 68Ga-peptides re-
spective therapeutic peptides.
Results: 68Ga-PSMA-617 was obtained with a yield of 48 % at EOS
(decay corr. 79 %). The labelling reaction was near quantitative, but
15 % (decay corr.) of 68Ga retained on the cationic exchange column
during processing. The labelling to 177Lu-PSMA-617 was quantitative,
there for the yield was >90 %. The radiochemical purity, determined to
be HPLC was 96 % (68Ga-PSMA-617) and 92 % (177Lu-PSMA-617) due
to detected impurities of labelled peptides. The detected amount of
free radionuclides were always <1 %. 68Ga-PSMA-617 and 177Lu-
PSMA-617 remained stable until the planned shelf live.
Conclusion: The introduced preparation of 68Ga-PSMA-617 and
177Lu-PSMA-617 using Scintomics GRP synthesizer and standard syn-
thesis sequences are robust and reliable processes, which meets the
GMP rules.
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Aim: Liposomes (LPs) have been extensively investigated as nano-
carriers for drug delivery. In this context, evaluation of their biodis-
tribution pattern after administration into living organisms is of
paramount importance. This can be achieved by incorporation of a γ-
emitter radioisotope followed by in vivo imaging using single photon
emission computed tomography (SPECT). Here, we present a method
for radiolabelling LPs with the γ-emitter 67Ga. Regional distribution
in the lungs after inhalation using a specially designed nebulisation
chamber was determined using SPECT-CT.
Methods: Gallium-67 (T1/2 = 3.26 days) was purchased from IBA-
Molypharma as 67Ga-citrate complex and converted into 67GaCl3
following a well established method.1 For the radiolabelling, 10 μL 8-
hydroxyquinoline (10 mM in EtOH) in 100 μL sodium acetate buffer
(100 mM pH 5.5, 150 mM NaCl) were added to 67GaCl3 (≈150 MBq
in 0.1 M HCl). Immediately after, 100 μL of DTPA-containing LPs
were added and the mixture was incubated at 37 °C for 1 hour.
67Ga-liposomes were purified by size exclusion chromatography
and radiochemical purity was assessed by radio-ITLC. Administra-
tion of the radiolabelled LPs was carried out under sedation using
an only-nose exposition device coupled to a chamber equipped
with a specially designed nebulizer. Biodistribution of 67Ga-
liposomes was investigated by whole body SPECT-CT imaging.
Dissection/gamma counting and ex vivo imaging experiments to
assess the percentage of the nebulised dose deposited in the lungs
and the accurate regional distribution, respectively, were also
carried out.
Results: Labelling efficiencies close to 45 % were achieved. After
purification, radiochemical purity exceeded 95 % in all cases. Biodis-
tribution data showed a uniform distribution of the labelled LPs in
both lungs at short times after inhalation. The percentage of the
nebulised LPs reaching the lungs was close to 0.5 %.
Conclusion: Uniform distribution of the labelled LPs in the lungs is
achieved with the new aerosol generator. The obtained data consti-
tute a promising starting point for using liposomes as nanocarriers
for antibiotics targeting the lungs of infected patients.
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Aim: SPECT imaging of dopamine transporters (DaT) with FP-CIT
(DaTscan) is an established method for the diagnosis of neurodegen-
erative parkinsonism. Quantification of DaTscan (semi-automatic or
full automatic) has been shown to reduce equivocal reporting of
DaTscan and can be used as an adjunct to visual assessment. The re-
cent published “European multicentre database of healthy controls”
[1] showed significant age-related effects and gender differences in
DaT levels in healthy controls. We developed a tool to integrate
those normal physiological variances in the quantification of a single
SPECT-examination. Furthermore the tool allows to build a large
database for further statistical analysis.
Methods: SPECT-acquisition was done on a GE Hawkeye dual head
gamma-camera. Quality control showed longitudinal uniformity and
centre of rotation within limits. SPECT acquisition and reconstruction
were performed in concordance with the parameters described in
the ENC-DAT study. Images were reconstructed without and with at-
tenuation correction (using Chang’s method). For further calculation
only the results of the AC images were used. Quantification was
done using BRASS fully automated functional brain analysis (Hermes,
Sweden).
Using standard Excel software (Microsoft Corporation, United States)
a macro enabled worksheet was developped which 1) allows easy in-
put of relevant parameters (including quantitative output of BRASS)
for an individual patient, 2) create a result page with numerical and
graphical results of the DaTscan-quantification and 3) builds a data-
base from each input session.
Results: In all patients (age ranging from 32 to 87 years; 31 male and
30 female patients) scheduled for DaTscan, quantification was per-
formed with age and gender correction. The procedure is standar-
dised and fully automatic and autonomously done by the medical
imager. Physicians can report DaTscan with greater diagnostic confi-
dence: all scans could be classified as normal or abnormal. A data-
base of 61 patients is build since start of this tool: further statistical
analysis will be performed in the future.
Conclusion: Integreation of age and gender differences in quantifica-
tion of DaTscan is feasible and applicable in clinical routine.
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Aim: To validate the cut-off value for the differentiation between
low grade and high grade glioma in patients undergoing O-(2-18F-
fluoroethyl)-L-tyrosine (18F-FET) PET/CT combined with MR imaging.
Methods: 232 Lesions (from 112 patients, mean age 54 years) were
included into this study. The tumor entities are astrozytoma (45),
ependymoma (2), ganglioma (1), glioblastoma (120), gliosarkoma (1),
oligoastrozytoma (32), oligodendroglioma (29) and undefined (2).The Philips software Intellispace Portal (ISP) was used to co-register
18F-FET PET data with most recent MRT images with a maximum
interval of 42 days. A circular background area with 5 cm diameter
drawn in the contra lateral hemisphere to glioma including white
and grey matter was suitable to define a LBR of 1,6 as threshold be-
tween tumor and normal tissue. For calculating the lesion-to-
background ratio (LBR), the SUV max of the lesion was divided by
the SUV mean of the background area. Clinical data on surgery, hist-
ology, chemotherapy, radiotherapy and WHO grade were obtained
from all patients.
Results: The mean LBR of low grade tumor was significantly lower
compared with the LBR of high grade tumor (2,38 vs. 2,83 p = 0,006).
The 95 % confidence interval ranged from 2,067 to 2,686 in low
grade tumors, and from 2,695 to 2,967 in high grade tumors, respect-
ively. The LBR cut-off value to differentiate between low grade and
high grade tumors was 2,7.
The mean LBR in patients without radiotherapy was not significantly
different compared to patients undergoing the 18F-FET PET scan dur-
ing or after radiotherapy (2,78 vs. 2,70 p = 0,560).
The mean LBR in patients without chemotherapy was significantly
higher than in patients undergoing the 18F-FET PET scan during or
after chemotherapy (2,93 vs. 2,61 p = 0,023).
Conclusion: This study confirms the validity of a cut-off LBR value of
2,7 for the differentiation of low grade and high grade glioma.
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Aim: To evaluate visually and semiquantitatively [11C]-methionine
(MET) PET and MRI for glioma grading in non treated patients.
Methods: A total of 166 glioma patients (93 men, 73 women, mean
age: 44.9, range 18–83.5 years) were included in this study. Patients
underwent a preoperative MET PET and MRI imaging between 2000
and 2014 at the Medical University of Vienna. MRI images were eval-
uated for contrast agent enhancement of the tumor. The PET scans
were evaluated visually and by means of SUV tumor to background
(T/N) ratios extracted from a cubic volume of interest (8 cm3). Follow-
ing T/N ratios were evaluated: T/Nstandard (i.e. SUVmax/SUVmean),
T/Npeak (i.e. SUVpeak/SUVmean), T/Nmax (i.e. SUVmax/ SUVmax)
and T/Npp (i.e. SUVpeak/SUVpeak).
Results: Our patient contingent was evenly distributed between low
and high grade tumors (46 % low, 54 % high grade) according to the
latest WHO definition (2007). Excluding oligodendrogliomas (ODG)
61 % of all gliomas without MRI contrast enhancement were low
grade and 76 % of gliomas with MRI contrast enhancement were
high grade gliomas. In ODGs only 58.5 % of non contrast agent avid
gliomas were low grade and 54.5 % with verifiable uptake of contrast
agent were high grade gliomas. Most frequently tumors were located
in the frontal (44 %) followed by the temporal lobe (41 %). Visually
EJNMMI Research 2016, Volume 6 Suppl 1 Page 13 of 18negative PET scans were predominantly found in low grade gliomas
(82 % of cases). Focal pattern with a branch and multifocal with
branches were mainly found in high grade gliomas (78 %, 70 % of
cases). All T/N ratios showed significant results for distinguishing low
from high grade gliomas (p < 0.001). T/Nmax and T/Nstandard per-
formed similar and slightly better than T/Npeak and T/Npp when evalu-
ated by AUC of the ROC analysis. Excluding ODGs thresholds of
1.26 T/Nmax and 2.16 T/Nstandard appeared as most applicable
(T/Nmax: detection rate 86 %; error rate 31 % resp. T/Nstandard:
detection rate 82 %; error rate 22 %).
Conclusion: [11C]-methionine PET is useful to distinguish between
low and high grade gliomas in non treated patients.A30
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Aim: PET/CT is increasingly used to evaluate multiple myeloma (MM)
bone lesions, however, 18F-fluorodeoxyglucose (FDG), the reference
radiopharmaceutical in oncology, shows in this indication relatively
low sensitivity. The aim of our pilot study was to compare FDG and
18F-fluorocholine (FCH) in detection of MM lesions at time of disease
relapse or progression.
Methods: This retrospective study assessed the results of FDG and
FCH imaging in 17 MM patients undergoing PET/CT for suspected re-
lapse or progressive MM. For each patient and each tracer, an on-site
reader and a blinded reader independently determined the number
of foci of tracer uptake in bone and the intensity of up to 5 foci as
given by their SUVmax and the corresponding target/non-target ratio
(T/NT).
Results: The blinded reader detected 63 foci for FDG versus 103 foci
for FCH (+64 %) whereas the on-site reader detected 66 foci for FDG
versus 102 foci for FCH (+55 %), the difference being significant in
each case (P = 0.002 and 0.008, respectively). Between-reader agree-
ment on the total number of foci was very high, with a kappa coeffi-
cient of 0.83 (CI 0.746-0.940) for FDG and an even higher coefficient
for FCH (0.93, CI 0.870-0.995). Measurement of uptake by the blinded
reader in the 54 foci that took up both tracers revealed a significantly
higher median SUVmax for FCH versus FDG [6.10, range (2.3-16); vs
4.65, range (1–20.6); P = 0.0007).
Conclusion: These findings suggest that PET/CT performed for sus-
pected relapsing or progressive MM would reveal more lesions when
using FCH rather than FDG.A31
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Aim: The objective of the study was to demonstrate the advantages of
SPECT/CT-aided sentinel lymph node mapping (SLNM) on metastaticnode detection and disease-free survival in patients with invasive
breast cancer.
Methods: Two hundred thirty-two patients with invasive breast can-
cer with clinically negative lymph nodes were included in this study
as they were referred for SLNM with 99mTc-nanocolloid. Of those pa-
tients, 118 had planar scintigraphy alone, and 114 had planar scintig-
raphy and low-dose SPECT/CT additionally.
Results: Between April 2002 and June 2011, 118 patients underwent
the standard SLNM technique. Between December 2009 and Decem-
ber 2011, 114 patients underwent the SPECT/CT technique. In the
SPECT/CT cohort, 139 SLNs were detected with planar scintigraphy
alone and 290 SLNs with additional SPECT/CT. In 5 patients, no SLN
could be detected with planar scintigraphy. In 4 of the last patients,
SLNs were identified with the aid of SPECT/CT. In the standard co-
hort, only 125 SLNs were detected. Thus, in the SPECT/CT cohort sig-
nificantly more SLNs per patient were removed than in the standard
cohort (2.25 vs. 1.89), and the number of further on identified meta-
static SLNs per patient was significantly higher (0.43 vs. 0.31). Conse-
quently, in the SPECT/CT cohort significantly more patients had
therapy change (axillary lymph node dissection) than in the standard
cohort (32 vs. 15) and the local relapse/metastasis rate in the SPECT/
CT cohort was lower than in the standard cohort (8.8 % vs. 26.3 %).
Accordingly, 4-year disease-free survival was significantly longer in
the SPECT/CT cohort (91 % vs. 74 %).
Conclusion: Among patients with breast cancer, the use of SPECT/
CT-aided SLNM correlated due to a better anatomical localization
and identification of planar not visible SLNs with a higher detection
rate of metastatic SLNs. This led to therapeutic consequences and,
therefore, a higher rate of disease-free survival.
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Aim: Evaluation of the advantages of time-of-flight (TOF) in 18F-FDG-
PET/CT in the detection and characterization of pancreatic lesions in
patients with suspected pancreatic cancer. Furthermore, the max-
imum standard uptake value (SUVmax) was assessed. TOF should
EJNMMI Research 2016, Volume 6 Suppl 1 Page 14 of 18improve image noise, local resolution and thus the demarcation of
small lesions.
Methods: TOF-18F-FDG PET/CT was prospectively performed in 20
patients with suspected pancreatic cancer. In all patients, a histo-
pathologic confirmation was made. PET/CT images were performed
30 and 90 min. p.i. including a diagnostic CT of the upper abdomen
with contrast medium and pancreas protocol. SUVmax of the le-
sions was measured and compared with and without TOF in the 30
and 90 min. p.i. images. Lesions with an increase of SUVmax on the
delayed images were assessed as malignant, whereas lesions with a
decrease of SUVmax were assessed as benign. The comparison of
TOF-PET/CT with standard PET/CT images and the determination of
cut-off values for malignant lesions were made using ROC-analysis.
Results: Of 20 patients 11 patients had malignant and 9 patients a
benign pancreatic lesion. In one patient IPMN could only be diag-
nosed correctly with TOF. Based on the histopathologic findings sen-
sitivity, specificity and diagnostic accuracy for TOF were 100 %, 67 %
und 85 % versus 90 %, 90 % and 90 % without TOF. ROC analysis of
SUVmax with TOF 30 and 90 min p.i. yielded a cut-off value of 4.5
and 4.7, respectively with a sensitivity and specificity of 89 % and
100 % and 91 % and 100 %, respectively. The area under the curve
(AUC)PET and AUCTOF-values showed no significant difference nei-
ther in the early nor the delayed images.
Conclusion: Among patients with suspected pancreatic cancer, the
use of TOF-PET/CT correlated due to a better anatomical localization
and identification of pancreatic lesions with higher sensitivity. How-
ever, TOF-PET/CT is of no additional use in differentiating malignant
and benign pancreatic lesions. To what extent patients can benefit
from the higher statistical weighting of the sensitivity should be ex-
amined in a greater patient population.References
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Aim: We propose a novel approach additional to inspection and para-
metric subtraction analysis aiming to avoid thyroid gland and thyroid
nodule artifact in parathyroid lesions scintigraphy.
Methods: 78 patients, median age of 58 (19–80) years, with clinical
diagnosis hyperparathyroidism (PHPT) and ultrasound positive report
of concomitant thyroid disease, underwent preoperative, dual- tracer:
99 m Tc-pertecnetat and 99mTc-MIBI, double- phase scintigraphy
(EANM guidelines 2009). Specially designed software, we developed,
examined ROI time/activity changes in matrix with different, optional
sizes, up to maximal resolution (1,5 mm); with automatic imaging sig-
nal preprocessing (linear fitted TAC logarithm, ensamble coupling)
and segmentation based on semi automatic TACs clustering of pixels
as well as fractal analysis for noice/motion artifacts and time activity
curves. We correlated our findings with PTH levels, histology results
and conventional scintigraphic findings: subtraction and visual inter-
pretation of planar images of neck and mediastinum in oblique sec-
tions, according to ultrasound PHPT localization and delayed scans in
one hour interval
Results: Following histopathology in A.: parathyroid autonomy 53/
78pts: solitary- 44pts, hyperplasia: 8pts- 7/8patients with two lesion
and 1/7 had all four lesions and one PT carcinoma; median lesion
volume was 796 mm3. B: thyroid – benign nodule only: adenoma
folliculare, colloides and cystica: 25/78(32 %)pts; malignancy: 15/
78(19 %)pts- papillary 7pts and one for medullary; C.: concomitant
PHPT and thyroid nodular disease occurred in 36/53pts, among
them 8pts had thyroid malignancies. Parathormone (PTH) was me-
dian 125,2 pg/ml (range 70- 658 pg/ml). Standard findings (subtrac-
tion, oblique planar scans and delayed phase) in total of 63 lesion
(in 53 pts) had 10 FN (mostly in hypeplasia PTA), and PPV was 81 %;
sensitivity 96 %, specificity 76 %. Using specially designed software,
thyroid TACs represented exponentially declining curves but para-
thyroid lesions had typical uptake pattern in the form of late phase
peak, independent to PTA volume and/or PTH levels. The ratio of
PTA-to-normal thyroid uptake at peak maximum was 1.35(±0.21). Pa-
rameters of optimal PHPT curve enabled visual interpretation. Fractal
theory was helpful in matrix 5x5 designing classifier dimension 1.1-1.3
for automatic procedure. A new processing method had PPV 97 %, sen-
sitivity 98 %, and specificity 96 %. The thyroid gland washout was up to
28 % in normal, adenoma or thyroid carcinoma tissue and their slope
analysis of TACs had equivocal negative slope: −0.04.
Conclusion: New quantification method and dedicated software as
well as high computational power facilitate the recognition of small
parathyroid lesions in the presence of concomitant thyroid nodular
disease, overcoming diagnostic problem present in conventional as
well as SPECT/CT and PET/CT imaging.
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Aim: Merkel cell carcinoma (MCC) is a rare aggressive tumor arising
from mechanoreceptors of the epidermis with a lower relative sur-
vival stage for stage than in melanoma. Distant metastases are re-
ported in 7 % of the patients with frequently involved sites being
distant lymph nodes, liver, lung and brain. Pancreatic involvement is
not common and the few cases reported in literature showed one or
multiple sites of FDG focal uptake. We report a case of a diffuse in-
volvement of the pancreas detected by 18F-FDG PET-CT in a patient
with MCC derived from gluteal skin region.
Methods: A 71 years-old male patient with a nodular lesion of about
7 cm on the right gluteus which was excised and diagnosed to be
MCC poorly differentiated with Ki67: 80 %. Immuno-histochemical
analysis demonstrated positive reaction for neuroendocrine markers
such as synaptophysin, CK20, NSE and chromogranin A, while nega-
tive for TTF-1 and CK7. Subsequently the patient underwent sentinel
lymph node biopsy with final diagnosis of metastasis of MCC in right
inguinal station. CT-scan at baseline was negative for distant metas-
tases but, in consideration of the high value of Ki 67 and the lymph
nodes metastases, 18F-FDG PET-CT, considered a promising func-
tional imaging modality for the evaluation of MCC, was performed.
Patient fasted for at least 6 hours before 18F-FDG administration
(blood glucose levels 82 mg/dl) and study was performed using an
integrated PET-CT device (Philips Medical System) at 60 minutes from
administration of radiotracer intravenously (298 MBq). CT was ac-
quired from the base of the skull to the thighs (120 kV, 50 mA) and
used for anatomical localization and attenuation correction of 3D-PET
emission data.
Results: PET/CT scan showed pathological uptake of the radiotracer
into multiple lymph nodes localized in the abdominal and pelvic
lymph node stations; in addition the images showed uptake of FDG
in a nodular lesion located between right gluteus muscles. The pan-
creatic gland presented a diffuse and intense uptake of radiotracer
(SUV 8.7), without significant morphological changes detected by CT
low dose, unlike what is reported in the literature. In according toPET-CT scan the oncologist decided to perform an adjuvant chemo-
therapy. PET-CT will be performed during and at the end of the treat-
ment for the evaluation of the response.
Conclusion: This case confirmes the incremental benefit of PET sta-
ging over conventional radiological imaging in the management of
MCC patients with unsuspected diffuse pancreas involvement.
Consent
Written informed consent was obtained from the patient for publica-
tion of this abstract and any accompanying images. A copy of the
written consent is available for review by the Editor of this journal.
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Aim: International thyroid societies recommend 18F-FDG PET/CT in
radioiodine-negative thyroid cancer patients with Tg ≥ 10 ng/ml.
However according to recent publications, it appears that no clear
cutt-off Tg value can be established (1). TSH stimulates thyrocyte me-
tabolism, Glut1 expression in thyroid cells, glucose trapping, and gly-
colysis and published data suggest that TSH stimulation significantly
improves the sensitivity of 18F-FDG-PET/CT (2). The aim of this study
was to assess the diagnostic efficiency of TSH-stimulated 18F-FDG
PET/CT in radioiodine-negative differentiated thyroid carcinomas
(DTCs) with different levels of TSH stimulated thyroglobulin (TSH-Tg).
Methods: A total of 109 patients with suspicion of recurrent DTC and
negative 131I whole-body scans underwent TSH-stimulated (TSH >
30 mU/L, thyroid hormone withdrawal) contrast-enhanced 18F-FDG
PET/CT (400 MBq 18F-FDG/70 kg body weight). 18F-FDG PET /CT was
indicated due to elevated TSH-Tg level or according to other suspicions
of DTC recurrence (persistently or progressively increased serum TgAb
level, high-risk patients, equivocal results of sonography). Patients (pts.)
were subdivided into 4 subgroups according to TSH-Tg: Tg < 2 ng/ml
(24 pts.), 2 ng/ml < Tg < 10 ng/ml (29 pts.), 10 ng/ml < Tg < 100 ng/ml
(42 pts.), and 100 ng/ml < Tg (14 pts.).
Results: In the whole group of 109 patients, TSH-stimulated 18F-FDG
PET/CT was true positive in 45 cases (41 %), 2 false positive findings
(2 %). 18F-FDG PET/CT correctly detected foci of thyroid carcinoma in
TSH-Tg subgroups: Tg < 2 ng/ml – 8/24 patients (33 %), 2 ng/ml < Tg
< 10 ng/ml – 9/29 patients (31 %), 10 ng/ml < Tg < 100 ng/ml - 19/42
patients (45 %), and 100 ng/ml < Tg - 11/14 patients (79 %). 18F-FDG
PET/CT examinations lead to changes in therapeutic strategy (mainly
indication of surgery) in 28 patients (26 %).
Conclusion: This study shows that TSH-stimulated contrast-enhanced
18F-FDG PET/CT is able to identify radioiodine-negative recurrences
or metastases of DTCs in an important part of patients with distinct
elevation of TSH-Tg. The detection rate of recurrences is lower in per-
sons with Tg < 10 μg/L or with other reasons of suspicion of metasta-
ses (including persistently or progressively increased serum TgAb
level), nevertheless the positive findings represent a significant part
of these patients. Therefore, this series indicates that it is not possible
to determine the lower Tg limit for an indication of TSH-stimulated
contrast-enhanced 18F-FDG PET/CT in patients with suspicion of re-
currence of differentiated thyroid carcinoma. It could be concluded
that TSH-stimulated 18F-FDG PET/CT is an efficient diagnostic tool in
DTC patients with a significant impact on therapy.
Table 1 (abstract A37).
Pb plate LEHR collimator Intrinsic
VI 0.58 4.35 3.1
Results were also confirmed with Simind Monte Carlo modelling.
Table 2 (abstract A37).
Pb plate LEHR collimator Intrinsic
VI 0.58 4.35 3.1
Results were also confirmed with Simind Monte Carlo modelling.
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Aim: It is well known that breast feeding is totally contra-indicated
following I131 treatment for thyrotoxicosis, since I131 is freely
expressed in breast milk. However lactation can continue for some
time after breastfeeding stops and this can lead to significantly in-
creased breast dose.
Methods: ICRP95 developed a comprehensive model for the lactat-
ing breast, and breast dose during lactation was calculated. For I131,
only one dose model was presented. This was based on normal 30 %
uptake by the mother, 270 ml/24 hr milk production, with a further
40 ml milk production stimulated by breast feeding.
Results: The breast dose without lactation for 600 MBq I131 (30%
uptake) is 36 mSv. The ICRP95 figure with their lactation model is
780 mSv, a 21x increase. Surprisingly, ICRP95 comment that the
increased breast dose is small in relation to overall effective dose.
Lactation I131 levels follow plasma levels. So for thyrotoxicosis with
an increased thyroid uptake of 55 % the calculated breast dose is
1.2Sv. For ablation with 1.1GBq, the rapid excretion of I131 leads to
some breast dose reduction. But calculation suggests a breast dose
of 830 mSv, still a high figure.
Conclusion: For I131 treatment, the lactation status needs to be consid-
ered to reduce breast dose. However suddenly stopping breastfeeding
is not recommended and Maternity advice should be sought. Most
women can reduce lactation to negligible levels in about 2 weeks with
help. In difficult cases, Cabergolin may be considered as an effective
mechanism, but can have side effects. Maternity advice is that this is
rarely needed. Although uncommon, this situation should be added to
local guidance.
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Aim: SeHCAT absorption studies have gained in popularity over re-
cent years. The capsule has a Se75 activity of only 370 kBq, therefore
the gamma camera is normally used intrinsically (no collimators).
However intrinsic counting leaves the crystals exposed, with the po-
tential for anything falling onto the crystal face causing expensive
damage. In addition there is the potential for sources, or for any low
level (50 kBq) Tc99m contamination on the bed, to interfere with the
measurement Some departments count with a LEHR collimator in
place but sensitivity is then very low, so counting times are longer
and the statistical error can become significant.
Methods: A new concept uses a uniform 2 mm lead plate as a crystal
cover, or ‘collimator’. This completely blocks any effect from other
Tc99m sources in the department. However the higher energy Se75
emissions (264 – 400 keV) can easily penetrate the lead sheet for count-
ing. The lead plate also provides complete protection for the crystal.Results: The sensitivity for Se75 (in a water-filled phantom) with the
lead plate is 7608 c/s/MBq. This is 10x the LEHR collimated count rate
(GE-LEHR, 766c/s/MBq). Even for a large BMI patient, a 60s count with
the lead plate system gives + −0.8 % (2std.dev) error on a 10 % ab-
sorption value. However the corresponding error with the LEHR colli-
mator is + −3.5 %. An error of + −1 % would need 1100s counting
time for the LEHR collimator.
A point source of Se75 was counted in varying positions and depths
in a water-filled phantom. The Variation Index (VI), (average modulus
of %differences) was calculated. The more uniform the spread of
values then the VI value is smaller. Table 1.
Conclusion: The sensitivity for Se75 (in a water-filled phantom) with
the lead plate is 7608 c/s/MBq. This is 10x the LEHR collimated count
rate (GE-LEHR, 766c/s/MBq). Even for a large BMI patient, a 60s count
with the lead plate system gives + −0.8 % (2std.dev) error on a 10 %
absorption value. However the corresponding error with the LEHR
collimator is + −3.5 % . An error of + −1 % would need 1100s count-
ing time for the LEHR collimator.
A point source of Se75 was counted in varying positions and depths
in a water-filled phantom. The Variation Index (VI), (average modulus
of %differences) was calculated. The more uniform the spread of
values then the VI value is smaller. Table 2.A38
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Aim: We did a retrospective survey of the results of F-18-PET-CTs and
CTs performed at our hospital between 07/2008 and 08/2014 for sus-
pected tuberculosis.
Methods: We included 197 patients (118 m, 79 f, age 53.7 ± 16.6 years
at first visit); persons with prior malignant disease were excluded.
They were scanned 50 min. past injection of (avg.) 300 MBq F-18-
FDG from skull base to mid-femurs; these results were compared to
diagnostic X-ray-CTs (including contrast enhancement where applic-
able) performed at the same visit or up to 4 weeks prior to the FDG-
PET. We used microbiological findings as well as clinical and further
(PET/)CT results to establish the diagnose independently.
Results: 83 patients showed no relevant uptake. In 21 we suspected a
malignoma, which was proven in 9 cases by surgery and histology. The
rest (105 patients) showed conspicuous focal uptake (SUV > 2.5), which
was interpreted by us or after exclusion of malignant disease as inflam-
matory (tuberculosis, sarcoidosis and non-granulomatous). In 35 cases
(18 m, 17 f, 45.4 ± 18 y) we do not only have proof of tuberculotic dis-
ease other than by FDG-PET, but also≥ 1 follow-up PET/CTs.
We stratified our results according to involved systems: lung and
pleura / LN intrathor. / LN extrathor. / bones / visceral organs / other
soft tissue. 1 patient remained without FDG-uptake, 15 showed 1 in-
volved system, 13 had lesions in 2, 1 in 3 and 5 in 4. The figures ex-
tracted from Xray-CT alone are 12/0 (incl. one false negative also
with FDG), 13/1, 9/2, 1/3, none with 4 or more involved systems.
EJNMMI Research 2016, Volume 6 Suppl 1 Page 17 of 18The best match was found in lung and pleural involvement: 15
patients were positive with both modalities (albeit including 2
discrepancies); 16 patients with mediastinal lymph node disease
were posotve according to FDG, but only 6 were morphologically
positive, too. 5/15 cases of extrathoracic LN, 1/7 with PET+ paren-
chymatous organs were radiologically suspect, as were 3/9 with
bone lesions.
Conclusion: Whole body F-18-FDG-PET/CT enhances the quality of
results in tuberculotic disease dramatically over X-ray methods alone.
Especially extrathoracic disease involvement is by far better docu-
mented by molecular imaging, with probably considerable impact on
treatment.
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Aim: A recent literature review has demonstrated that 18F-FDG PET/
CT is becoming a very useful diagnostic tool in primary or material
infection. In this study we evaluate the presence of infection in pa-
tient whit a mechanical heart detected by 18F-FDG PET/CT.
Methods: A 38 years-old male patient with a severe heart failure due
to Becker’s muscular dystrophy underwent HeartWare ventricular as-
sist system (HVAD) implant in 2012 as a bridge heart transplantation.
Three years later, he complains of abdominal pain along the per-
cutaneous driveline with associated infection local symptoms and
abnormal biological parameters (VES and PCR). As conventional im-
aging (Ultrasonography, CT) and 99mTc-WBC scan were inconclusive,
the heart-surgeons proposed to perform an 18F-FDG PET/CT to
evaluate the extention of active infection process, on the basis of
studies showing that cells involved in infection and inflammation, es-
pecially neutrophils and the monocyte/macrophage family, are able
to express high levels of glucose transporters, especially GLUT1 and
GLUT3, and hexokinase activity (in according to european guide-
lines). Patient attended a carbohydrates-free diet 48 hours before the
exam, to switch miocardical glycolitc metabolism to free fatty acid.
He fasted for at least 6 hours before 18F-FDG administration (blood
glucose levels 97 mg/dl). Study was performed using an integrated
PET-CT device (Philips Medical System) at 60 minutes from adminis-
tration of radiotracer intravenously (323 MBq). CT was acquired from
the base of the skull to the thighs (120 kV, 50 mA) and used for ana-
tomical localization and attenuation correction of 3D-PET emission
data. A second acquisition after 180 minutes was acquired to evalu-
ate the SUV value variation.
Results: PET/CT scan showed linear area of FDG accumulation
along the driveline, extending intracutaneous right abdomen re-
gion to the intracardiac implantation; the uptake has increased
significantly in the late acquisition (ΔSUV 25 %). Therefore PET-CT
images were not able to evaluate the distribution of the radio-
tracer in miocardical wall near cardiac pump for the interference
generated by metallic components on CT recostruction. Non at-
tenuation corrected images confirmed the pathological uptake in
driveline and exclude abnormal accumulation of radiotracer in the
cardiac pump. In according to PET-CT scan the heart-surgeons de-
cided to perform a cutaneous biopsy in order to identify micro-
organism for adapted antibiotic treatment. A new PET-CT will be
performed as follow-up.
Conclusion: 18F-FDG PET-CT could be an appropriate imaging mo-
dality for management infection diseases in Patient with HVAD.
Consent
Written informed consent was obtained from the patient for publica-
tion of this abstract and any accompanying images. A copy of the
written consent is available for review by the Editor of this journal.References
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Aim: ‘Poisson-resampling' software modifies images to represent
reduced time/activity. Such software is now being made available
by companies and allows for retrospective studies of changes to
image quality with reducing time or activity. Previous testing of
the software has relied on checking acquired floods. However
these may have non-uniformities and do not include very low
counts/pixel. Checking the performance at very low counts/pixel
is particularly relevant for nuclear medicine studies e.g. bone
scans where approximately 50 % of pixels are 1–10 counts/pixel.
We have developed appropriate statistical tests for Poisson resampling
software.
Methods: Our alternative analysis used simulated uniform images
created with the same count/pixel (i.e. 'noiseless floods'). This
allowed us to statistically test the Poisson resampling software on
pixel values down to one count/pixel. Since the images are noiseless,
i.e. without the standard Poisson noise of nuclear medicine images,
statistical testing was different. Mathematically it can be shown that
the Poisson software should generate a binomial (Gaussian) distribu-
tion with mean sqrt(f*(1-f)*M)), f = Poisson fraction, M = count/pixel
of original image. Resampled data was tested using χ2 analysis.
Results: The Poisson resampling software showed excellent agree-
ment with the expected binomial distributions for all values exam-
ined, including the lowest of 1 count / pixel (p > 0.1 for all cases).
Conclusion: This independent validation technique proves Poisson
resampling software correctly generates expected noise characteris-
tics even down to 1 count/pixel. This is reassuring given the increas-
ing applications of such software, and indicates that the Poisson
software can reliably be used in studies to examine the effects of re-
duced time or activity.
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Aim: The paper is to discuss some current specific difficulties in
assessing the radiation exposure received by workers handling radio-
pharmaceuticals at nuclear medicine clinics or departments engaged
in the PET/CT examinations. This staff is daily coming into contact
with unsealed radioactive material which results in its whole-body
exposure as well as in the exposure of extremities, especially the skin
of hands.
Methods: The present situation in radiation exposures of extremities
of radiation workers has been summarized and the specific problems
in monitoring the skin dose identified. The equivalent dose to the
skin of hands of workers at selected nuclear medicine departments
in the Czech Republic have been measured and compared against
relevant dose limits.
Results: The distribution of the dose on the surface of fingers at
specified positions monitored by TLDs is presented. The relation
between the readings of finger dosimeters and the maximum
skin exposure was analysed and interpreted. The preliminary results
have shown that about 5 % of workers handling F-18 labelled radio-
pharmaceuticals may exceed the current dose limit for the skin.
EJNMMI Research 2016, Volume 6 Suppl 1 Page 18 of 18Conclusion: The results of this study are consistent with our previous
measurements [1] and other recently published communications (e.g.
[2]) which also concluded that some nuclear medicine workers may
not comply with the regulatory requirements relevant to the skin ex-
posure. Due attention should be paid to a more realistic assessment
of the skin doses taking into account the correction factors between
the reading of ring dosimeters and the maximum skin dose as well
as the possible impact of the radioactive contamination of gloves.References
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